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ABSTRACT

Pax-5, a member o f the Pax family of transcription factors, plays an important
role in B cell development and differentiation.

The gene produces four alternatively

spliced variants (Pax-5a, Pax-5b, Pax-5d, and Pax-5e) including one of the most
extensively studied regulators o f B-lymphopoiesis, the B-cell-specific activator protein
(BSAP). BSAP is encoded by the predominant Pax-5a isoform, and while its roles are
well defined, the regulatory functions o f the remaining Pax-5 isoforms are not clearly
understood.
The study presented here pursued two goals. First, the transactivation properties
o f the alternative isoform Pax-5d were determined in vivo using transient transfections.
Evidence is provided indicating that Pax-5d has a function opposite to that o f Pax-5a and
the two isoforms may compete for binding to Pax-5 recognition sequences. The second
goal o f the project was to investigate the regulatory function o f Pax-5 isoforms in resting
and LPS-activated B cells using various B cell lines and splenic B lymphocytes.
Experimental data demonstrates that, as mature B lymphocytes progress to the plasma
cell stage, the ratio o f different Pax-5 proteins changes possibly reflecting a shift toward a
higher concentration o f transcriptionally inert and/or dominant-negative isoforms. Based
on these results, the author o f this thesis hypothesizes that the alternative splice forms of
Pax-5 differentially regulate the activity o f Pax-5a/BSAP.
regulation

may

include

post-translational

modifications

Other means of Pax-5a
that

alter

stability

and

transactivation properties o f this isoform.
In addition, this work contains a description o f several preliminary studies which
include the following: i) development o f a novel staggered transfection approach; ii)
comparative analyses o f the expression patterns o f Pax-5 proteins and their DNA-binding
activities in activated B cells from young and aged mice; iii) analyses o f Pax-5 proteins in
LPS-activated immature B cell line W EHI-231; and iv) pilot characterization of the novel
Pax-5X species. The discussion o f the results includes a model of Pax-5 regulation and
suggestions for future investigations.

LIST OF ABBREVIATIONS

aa:

amino acid(s)

BCR:

B cell receptor

BSAP:

B cell-specific activator protein

CAT:

chloramphenicol acetyltransferase

EMSA:

electrophoretic mobility shift assay

Ig:

immunoglobulin

ivt:

in vitro translated

LPS:

lipopolysaccharide

kb:

kilobase

kD:

kilodalton

nt(s):

nucleotide(s)

O-GlcNAc:

O-linked N-acetylglucosamine

SDS-PAGE:

sodium dodecyl sulfate- polyacrylamide gel electrophoresis

SRB(s):

small resting B cell(s)

NOTE TO THE READER

The work presented in this thesis consists of several related projects that explore
Pax-5 activity and function. Some of the more interesting findings of these investigations
are reported in the form o f a manuscript titled Functional Analyses o f Alternative
Isoforms o f the Transcription Factor Pax-5 (by Marina A. Lowen and Patty Zwollo).
This manuscript is currently in preparation for submission and is included here as
Chapter II. Due to the format chosen for this thesis, some of the information provided in
the manuscript (Chapter II) may also appear in the Literature Review or General
Discussion (Chapters I and IV, respectively). In addition, the Discussion section of the
manuscript is less detailed than might be expected for a thesis. However, all appropriate
considerations concerning the experimental findings o f this project are addressed in detail
in the General Discussion (Chapter IV), and the reader is encouraged to refer to that
section for a more comprehensive examination o f the results in light o f the relevant
research reported in the current literature.
Additional projects that were performed independent of the manuscript are
presented in Preliminary Studies (Chapter III).

This chapter describes on-going

experiments and pilot studies that examine the function of Pax-5 isoforms using
alternative approaches.

Conclusions based on all the data presented in the thesis are

incorporated into the General Discussion (Chapter IV).

The collective results of all

projects were used to construct the proposed model o f Pax-5 function and regulation.

x

Function and Regulation o f Alternative Isoforms o f the Transcription Factor Pax-5
During B Lymphocyte Differentiation.

2

CHAPTERI
Literature Review

B lymphocytes are the major players of the humoral immune response, which is
directed to the detection and elimination o f extracellular pathogens and foreign antigens.
The main distinguishing characteristic o f cells o f the B lineage is their ability to
synthesize and secrete immunoglobulin (Ig) molecules, the antigen-specific antibodies
present on the B cell membrane. Interaction of immunoglobulins with antigens triggers
activation o f B cells followed by their proliferation and differentiation into either
antibody-secreting plasma (effector) cells or memory B cells (Rudin and Thompson,
1998; Liberg and Sigvardsson, 1999).
The molecular mechanisms leading to B cell development and activation are
complex and involve a number of highly coordinated regulatory signals that direct B
lymphocytes through various stages of differentiation. These signals include the external
cues provided by extracellular growth factors and cell-cell contact, and intracellular
control executed by transcription factors which direct stage-specific gene expression
(Reya and Grosschedl, 1998). Transcriptional regulation of B lymphopoiesis has been
studied extensively by both molecular and genetic approaches, and a wide variety of the
relevant transcription factors have been identified in recent years.

The role o f many

transcriptional regulators has been determined through studies o f mice carrying targeted
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mutations in genes encoding proteins that direct lineage- and stage-specific gene
expression. Mutational analysis has proven invaluable tool in determining genetic targets
and elucidating the functional hierarchy and redundancy of specific transcription factors.
A number o f current investigations focus on identifying intracellular signaling pathways
that regulate the activity o f transcription factors and their interactions with other proteins.
Further understanding

o f regulatory

mechanisms

involved

in development and

differentiation o f the B cell lineage will provide increased insight into various aspects of
a productive immune response and help to determine a link between B cell anomalies and
pathological states including cancer, autoimmune disorders, and immunodeficiencies.

1. Stages o f B lym phocyte developm ent
Generation o f an effector B cell is preceded by several stages of maturation as
determined by distinctive growth factor requirements, sequential Ig gene rearrangements,
and expression of specific sets of cell-surface markers (reviewed in Kruisbeek and Storb,
1994; Rolink and Melchers, 1996; Reya and Grosschedl, 1998; Liberg and Sigvardsson,
1999; Hagman et al., 2000). Progression through these stages occurs in the bone marrow
and does not require the presence of antigen. The earliest B cell progenitors (pro-B cells)
arise from lymphoid stem cells which originate from pluripotent hematopoietic stem cells
committed to the lymphoid lineage (Figure 1.1).

The commitment to lymphoid

development is regulated by several transcription factors which include basic helix-loophelix proteins E2A and early B cell factor (EBF), Ets family transcription factor P U .l,
and zinc-finger containing products o f the Ikaros gene (Reya and Grosschedl, 1998;
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Rudin and Thompson, 1998). The main characteristic of pro-B cells is the expression of
a transmembrane protein tyrosine phosphatase B220 and surface antigens AA4.1 and
CD43 (Reya and Grosschedl, 1998).

The Ig genes of these progenitors remain in

germline configuration and produce sterile transcripts from the heavy-chain (IgH) locus
(Liberg and Sigvardsson, 1999).
Proliferation and differentiation o f pro-B cells into precursor B cells (pre-B cell
stage) is accompanied by activation o f the Ig gene recombination machinery and
rearrangements at the IgH loci, which is facilitated by the expression o f recombinase
enzymes Rag-1 and Rag-2. B cell precursors are defined by the presence o f the pre-B
cell receptor (pre-BCR) on the plasma membrane.

The pre-BCR of early pre-B cells

consists o f a rearranged IgH chain associated with surrogate light chains, X5 and VpreB,
and accessory polypeptides Iga and Ig(3. In addition to pre-BCR components, pre-B cells
express genes which code for proteins involved in pre-BCR signaling such as the Src
family tyrosine kinases (Blk, Lyn, Syk, and Fyn), CD 19, CD20, CD22, and CD72 (Li et
al., 1993; Liberg and Sigvardsson, 1999).

Functional pre-BCR and its signaling

components play an important role in positive selection of pre-B cells with productive
IgH gene rearrangement (Melchers et a l., 1995).
Positively selected pre-B cells (late pre-B cells) undergo Ig light (IgL) chain
recombination and enter the next stage o f differentiation, the immature B cell stage.
Cells that failed to generate a functionally rearranged IgH gene will undergo
developmental arrest followed by programmed cell death, or apoptosis (Rudin and
Thompson, 1998; Scaffidi et al., 1999). Immature B lymphocytes possess a fully formed
and functional B-cell receptor (BCR) represented by a membrane-bound IgM with a
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particular antigenic specificity. At this stage, the cells are negatively selected against
self-specificity and may undergo receptor editing which rescues some of the autoreactive
B lymphocytes through an additional round o f IgL gene rearrangement (Melchers et al.,
1995; Hertz and Nemazee, 1998).

After receptor editing, all the cells with an

autoreactive IgM are eliminated by apoptosis within the bone marrow (Rudin and
Thompson,

1998). The surviving lymphocytes differentiate into mature B cells

characterized by the presence of antigen-specific IgM and IgD coexpressed on the
membrane, and are capable o f responding to cognate antigenic stimulation.
Mature, naive B cells emerge from the bone marrow into the circulating blood
and lymph and enter the secondary lymphoid organs where they can either undergo
antigen-induced activation or, in the absence of antigen, be eliminated by apoptosis
(Kruisbeek and Storb, 1994). The mature B cell stage, as well as all subsequent stages of
B cell development, is antigen-dependent.

During the antigen-dependent phase,

differentiation o f mature B lymphocytes may either be initiated by cross-linking o f the B
cell antigen receptor complex (thymus-dependent antigens), or through direct stimulation
by

certain

cytokines

in the

presence

o f B cell

mitogens

lipopolysaccharide (LPS) (thymus-independent antigens).

such

as

bacterial

The signal-transduction

pathways are quite different for each route of activation and, in many cases, are not fully
understood.

Activation o f B cells by the thymus-dependent mechanism is antigen-

specific and requires interaction with helper T cells within germinal centers that form in
the spleen and lymph nodes in response to antigenic stimulation (Rudin and Thompson,
1998).

The activation process triggers a number of important changes including Ig

isotype class switching, antibody affinity maturation, plasma cell differentiation, and
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generation o f memory B cells (Liberg and Sigvardsson, 1999; Hagman et a l., 2000). In
contrast, mitogenic stimulation is independent of antigenic specificity o f B cells and does
not require contact with T lymphocytes. The immune response to thymus-independent
antigens is generally weaker due to a lack of class switching and absence o f long-lived
memory cells (Hodgkin and Basten, 1995).

Regardless of the type o f antigen, activation

signals always trigger a cascade o f events that result in proliferation and further
differentiation o f mature B lymphocytes into plasma cells, highly differentiated effector
cells capable o f antibody secretion (Kruisbeek and Storb, 1994; Liberg and Sigvardsson,
1999).
While plasma cells have been studied extensively, the characterization of
memory B cells remains elusive due to a limited number of well-defined membrane
markers specific for this population and the consequent difficulties in isolation and
purification o f these cells. The differentiation pathways leading to formation o f memory
cells are poorly understood. Some evidence suggests that generation o f either plasm a or
memory B cells is influenced by extracellular signals provided by certain cytokines (e.g.,
IL-6) or receptor ligands (e.g., CD40L, OX40L) (Arpin et al., 1995; Dutton et al., 1999).
Other findings indicate that memory B cells may arise from a different lineage than
plasma cells (Klinman,

1997).

In general, memory B lymphocytes possess a

characteristic CD27 cell-surface marker in addition to diverse isotypes o f Ig, various
adhesion molecules, and high levels of complement receptors (Dutton et al., 1999;
Agematsu et al., 2000).

Memory B lymphocytes represent a population of long-lived

high-affmity resting cells which, upon their re-exposure to target antigen, can
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differentiate into antibody-secreting plasma cells constituting the basis for a secondary
immune response (Rudin and Thompson, 1998).

Figure 1.1 (see next page): Stages of normal murine B cell development. Distinct
stages o f B lymphocyte development are determined by the status o f immunoglobulin
(Ig) genes and expression o f the specific sets of genes (Liberg and Sigvardsson, 1999;
Hagman et ah, 2000). Antigen-independent differentiation of B cells from hematopoietic
stem cells into immature B cells takes place in the bone marrow. During these stages,
formation o f a functional pre-BCR and BCR on the cell surface facilitates positive and
negative selection o f lymphocytes with productive Ig rearrangements. Activation and
differentiation o f mature B lymphocytes into plasma cells is an antigen-dependent
process which occurs in the peripheral lymphoid organs and culminates in secretion of
large quantities of antigen-specific antibodies (slg). Expression patterns o f selected cell
surface markers and accessory proteins, as well as several important transcription factors,
are indicated. IgH, immunoglobulin heavy-chain loci; IgL, immunoglobulin light-chain
loci; g-IgH(L), immunoglobulin in germline configuration; mlg, membrane-bound
immunoglobulin molecule; slg, secreted immunoglobulin molecule.
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2. Pax-5 (BSAP) as the “ m aster regulator” of B cell developm ent
2.1 Pax family o f genes.
A number o f transcription factors regulate lineage- and differentation-stagespecific expression o f the genes involved in B lymphopoiesis (Reya and Grosschedl,
1998; Liberg and Sigvardsson, 1999). Among these factors are the products o f the Pax-5
gene which encodes one o f the most critical transcriptional regulators, the B-cell specific
activator protein (BSAP). Pax-5 is a member o f a family of genes which encode nuclear
transcription factors involved in development, organogenesis, morphogenesis, and pattern
formation (Strachan and Read, 1994). The Pax family consists o f nine members {Pax-1
through Pax-9) all o f which share an e v o lu tio n ary conserved N-terminal DNA-binding
region o f 128 amino acids comprising the paired domain (Walther et a l., 1991). The Pax
genes have been classified into four paralogous groups (Figure 1.2) based on structural
similarities within the paired domain and on the presence or absence o f the centrallylocated octamer and homeodomain motifs (Dahl et al., 1997).

Genes within each

subclass show similar patterns of expression during embryogenesis and are highly
homologous in their paired domain sequence (Walther et al., 1991).
The Pax-2, Pax-5, and Pax-8 genes comprise a group o f closely related Pax genes
which contain a complete octapeptide m otif and a truncated homeodomain (Figure 1.2;
Adams et al., 1992; Strachnan and Read, 1994). The paired domains within the Pax2/5/8 subclass show 90-95% homology in the amino acid sequence, and, as a result, the
three proteins recognize almost identical DNA sequences (Walther et al., 1991; Kozmik
et al., 1993). Since the spatial and temporal expression patterns o f the Pax-2, Pax-5, and
Pax-8 genes overlap partially during early mouse development (Nornes et al., 1990;
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Classes of Pax
genes

Class I

Pax-1
Pax-9

Class II

Pax-2
Pax-5
Pax-8

Paired dom ain

O ctam er

H om eodom ain

N

C

N

C

Class III

Pax-3
Pax-7

N

C

Class IV

Pax-4
Pax-6

N

— C

Figure 1.2: Classes of Pax family of genes. Vertebrate Pax genes have been classified
into four classes (I through IV) based on the presence or absence of the octamer sequence
and homeodomain homology region. Pax-1 and Pax-9 genes have no homeodomain and
thus belong to the same class, Class I. Genes of Class II, Pax-2, Pax-5, and Pax-8,
contain a partial homeodomain with only one a-helix present. Pax-3 and Pax-7 form
Class III and possess the octamer sequence and the complete homeodomain. Class IV is
represented by Pax-4 and Pax-6 which have the complete homeodomain but lack the
octamer. Genes within each class contain a highly homologous DNA-binding motif, the
paired domain. The binding specificity o f the paired domain varies between the classes,
as is depicted by different patterns.
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Plachov et al., 1990; Asano and Gruss, 1992), their products may have either cooperative
or redundant function in regulation o f target genes. For example, cooperation of Pax-2
and Pax-5 has been shown to be essential for normal midbrain and cerebellum
development (Urbanek et a l., 1997), while Pax-2 and Pax-8 have been postulated to
regulate the same genes in kidney cells (Kozmik et a l., 1993).

2.2 BSAP: discovery, expression patterns, and functions
The transcription factor Pax-5 was originally identified as a mammalian homolog
o f the sea urchin tissue-specific activator protein (TSAP) which is involved in regulation
o f late histone gene (H2A-2.2) expression in sea urchins (Barberis et al., 1990).

The

expression of the newly discovered factor was observed in cells of the B lymphoid
lineage with the exception o f terminally differentiated plasma cells.

Furthermore, this

TSAP homolog was shown to bind DNA in nuclear extracts derived from pro-B, pre-B,
and mature B lymphocytes. As no expression or DNA-binding activity was detected in
cells o f either erythroid or T lymphoid lineages, the novel protein was named B-cell
specific activator protein (BSAP) (Barberis et al., 1990).

Further biochemical

purification and characterization of BSAP revealed that it is encoded by the Pax-5 gene
(Adams et al., 1992).
The earliest expression o f Pax-5 is detected in the developing central nervous
system where it is temporally and spatially regulated (Asano and Gruss, 1991; Adams et
al., 1992). Pax-5 transcripts are also found in fetal liver and, later, in all B-lymphoid
tissues and testis o f adult mice (Adams et al., 1992). Within the B cell lineage, Pax-5 is
expressed during early stages o f B cell development, from the pro-B-cell up to the mature
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B-cell stage, but is greatly downregulated or absent in plasma cells (Barberis et al.,
1990).
Some important regulatory functions of Pax-5 were determined through the
analysis o f Pax-5-/- knockout mice (Urbanek et al., 1994). Consistent with its expression
pattern, Pax-5 has been shown to play an essential role in B cell lymphopoiesis and
midbrain development. Inactivation o f the Pax-5 gene in mouse resulted in abnormalities
o f the posterior midbrain region and in a complete block o f B cell development.
Significantly, Pax-5-/- mutant mice failed to produce small pre-B, mature B, and plasma
cells, although they could still generate B220+ cells indicating developmental arrest at
the pro-B stage.

The lack of Pax-5/BSAP was also correlated with alterations in the

expression o f some o f its target genes, most notably the CD 19 gene which was not
expressed in the knockout mice (Urbaneck et al., 1994; Nutt et a l 1997). The Pax-5
mutation also inhibited VH-to-DnJn recombination and antibody production, indicating
the involvement of this transcription factor in the regulation of expression and
rearrangement o f Ig-gene (Urbanek et al., 1994; Nutt et al., 1997). Thus, the study of
Pax-5-/- mutant mice revealed that Pax-5 is a critical factor for progression o f B cell
differentiation beyond the pro-B stage (Figure 1.3).
In addition to its role in B-lymphopoiesis, Pax-5 has been implicated in activation
and proliferation o f B lymphocytes.

Introduction o f Pax-5 anti-sense oligonucleotides

into mature B cells causes decreased BSAP expression and subsequently leads to a
significant reduction in LPS-induced cell proliferation (Wakatsuki et al., 1994).

This

observation is in agreement with other studies of the Pax gene family which indicate that
one o f the important functions o f Pax genes is initiation of cell proliferation (Dahl et al.,
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1997). Deregulation o f these genes often results in cell transformation and development
o f tumors.

Thus, altered expression of Pax-5 has been detected in medulloblastomas,

astrocytomas, and some lymphomas (Kozmik et al., 1995; Stuart et al., 1995a; Busslinger
et al., 1996; Mahmoud et al., 1996; Krenacs et al., 1998). Furthermore, Pax-5, as well as
Pax-2 and Pax-8, have been shown to suppress p53, a tumor suppressor gene that is
essential for controlled cell proliferation, apoptosis, and protection against oncogenic
transformation (Stuart et al., 1995b; Lambert et al., 1998). Based on this finding, it has
been proposed that high levels of Pax-5 expression are required for prevention o f p53mediated apoptosis during early stages of B cell development when rapid cell growth is
necessary for attainment o f critical cell mass (Stuart et al., 1995b).

Conversely, the

reduced expression o f Pax-5 alleviates p53 inhibition allowing for lymphocyte selection
and

further differentiation.

During

the

final

stages

of B

cell

development,

downregulation o f Pax-5 activity is required for terminal differentiation of mature
activated B cells into plasma cells that are capable o f Ig isotype class switching and high
antibody production (Usui et al., 1997; Cogne et al., 1994; Stuber et al., 1995).
A recent study by Nutt et al. (1999) has revealed an essential role o f Pax-5 in Blineage commitment during the earliest stages o f B lymphopoiesis. Pax-5-/- pro-B cells
(derived from Pax-5 knockout mice) were shown to have characteristics of a
hematopoietic progenitor with broad lymphomyeloid developmental potential, including
the expression o f genes from different lineage-affiliated programs.

Under specific in

vitro conditions with provided growth requirements, the uncommitted progenitors can be
induced to differentiate into distinct cell lineages such as monocytes, granulocytes and
natural killer cells.

However, reconstitution o f Pax-5 activity in Pax-5-/- pro-B cells
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leads to repression o f lineage-promiscuous gene expression and subsequent restriction of
developmental plasticity in favor of the B-lymphoid lineage.

Thus, during early

differentiation events, Pax-5 simultaneously functions as an activator o f B-cell specific
genes and a repressor o f inappropriate expression of other hematopoietic genes.
Functions o f Pax-5 important for B lymphocyte development and differentiation are
summarized in Figure 1.3.

2.3 Pcix-5 target genes
Pax-5 binding sites have been identified on the promoters o f several B-cellspecific putative target genes including CD 19, mb-1, VpreB, A5, Ig J chain, and blk
(reviewed in Hagman et al., 2000).

In addition, Pax-5 plays an important role in

regulation o f the Ig genes: binding sites have been identified on Ig heavy chain 3 ’ C a and
Ig light chain

k3

’ enhancers, Ig a and s germline promoters, and in multiple Ig switch

regions. Other Pax-5 targets include th e p53 tumor suppressor gene (Stuart et al., 1995b).
genes encoding transcription factors hXBP-1 (Reimold et al., 1996), LEF-1 and N-myc
(Nutt et al., 1998), as well as the gene encoding the cell surface protein PD-1 (Nutt et al.,
1998).
Depending on the target gene and/or developmental stage of the B cell, Pax-5
may function as an activator, repressor or docking protein as determined by the presence
and activity o f other transcription factors. Among the positively regulated Pax-5 targets
are genes encoding pre-BCR/BCR components and molecules associated with BCR
signaling such as the CD19 co-stimulatory receptor (Kozmik et al., 1992), components of
the surrogate light chain VpreB and X5 (Okabe et al., 1992; Tian et al., 1997), and protein
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Figure 1.3: Functions of Pax-5 (BSAP) in B cell differentiation (see next page). Pax5 is expressed during early stages o f B cell development (from pro-B to mature B), but
greatly downregulated in plasma cells. At the earliest stages of differentiation, Pax-5 is
thought to direct the commitment of hematopoietic lymphoid progenitors toward the Blymphoid lineage by repressing lineage-promiscuous genes such as M-CSF-R. During
antigen-independent stages o f B cell development, Pax-5 regulates a number o f B-cell
specific genes that encode pre-BCR/BCR components and proteins involved in BCR
signaling. B cell development is blocked at the pro-B cell stage in Pax-5-/- knockout
mice. Pax-5 has also been speculated to have a function in pro-/pre-B cell proliferation;
however, the mechanism o f this regulation is unclear. During antigen-dependent phase,
Pax-5 is involved in activation and proliferation of mature B lymphocytes and Ig heavy
chain class switch recombination. Downregulation of Pax-5 expression during the
plasma stage cell results in relief o f its repressor function, which is especially important
for production and secretion o f antibodies. (+), positively-regulated Pax-5 target genes;
(-), negatively-regulated Pax-5 target genes.
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tyrosine kinase Blk (Zwollo and Desiderio, 1994). In contrast, overexpression o f Pax-5
inhibits the expression o f the Ig J-chain gene (Rinkenberger et al., 1996), while its
downregulation activates the IgH 3’a enhancer (Singh and Birshtein, 1993; Neurath et
a l., 1994), illustrating in both cases the repressor function o f Pax-5. Pax-5 also functions
as a repressor o f PD-1 and hXBP-1 genes (Reimold et al., 1996; Nutt et al., 1998) and
may be a key factor in inhibition of alternative lineage choices during commitment of
hematopoietic progenitors to B lymphopoiesis (see Section Z 2; Nutt et al., 1999).
As a docking protein, Pax-5 forms a complex with Ets-1 and functions as a
recruiter in positive regulation o f the mb-1 gene which encodes the Iga subunit of the
BCR (Fitzsimmons et al., 1996).

Similarly, it can interact with co-repressors of the

Groucho family and may recruit them for inhibition o f the negatively regulated Pax-5
target genes, including the M-CSF-R gene that encodes the myeloid cytokine M-CSF
receptor (Eberhard et al., 2000). Curiously, the transcription of some genes {mb-1, PD/, LEF-1) can be regulated with equal efficiency by either full-length Pax-5 protein or the
truncated paired domain polypeptide PRD (Nutt et al., 1998).

This finding is an

indication o f the recruiter function o f Pax-5 and yet another piece o f evidence for the
intricate complexity of pathways and interactions involved in B-cell-specific gene
regulation.

2.4 Pax-5 protein functional domains
The main distinguishing characteristic o f the Pax family of transcription factors
is the paired domain. Mutational analysis of Pax-5 and its DNA recognition sequences
revealed that this 128-amino acid DNA-binding m otif has a bipartite structure with
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distinct amino- and carboxy-terminal domains that bind to half-sites in adjacent major
grooves o f the DNA helix (Czerny et al., 1993). This structure has been confirmed by Xray crystallographic analysis o f the paired domain-DNA complex, which has also
demonstrated that each subdomain is composed of a helix-turn-helix m otif resembling the
structure o f the homeodomain (Xu et al., 1995).

For different members of the Pax

family, the specificity o f DNA-binding is achieved through recognition o f differential
target sequences as well as through cooperation between the paired domain and the
homeodomain (Jun and Desplan, 1996).

Those Pax proteins that contain a full

homeodomain (i.e., Pax-3, Pax-4, Pax-6, and Pax-7) have the ability to utilize that region
in different combinations with either one or both paired subdomains for differential
binding o f DNA sequences (Jun and Desplan, 1996). In contrast, DNA-binding of the
proteins without a complete homeodomain, such as the members o f Pax-2/5/8 subfamily,
has to rely entirely on both subdomains of the paired m otif (Czerny et al., 1993; Epstein
et al., 1994; Xu et al., 1995).
Despite the differences in binding mechanisms and subclass-specific preferences
for binding certain sets of nucleotides, consensus sequences for the Pax proteins show an
unusual amount o f degeneracy. For example, medium- or low-affinity binding sites for
Pax-5/BSAP occur every 1-2 kb in the mouse genome; however, the only sites that have
functional relevance are those found in the vicinity of B cell-specific genes (Busslinger
and Urbanek, 1995). Furthermore, none of the naturally occurring Pax-5 binding sites
conform completely to the consensus recognition sequence (Czerny et al., 1993;
Busslinger and Urbanek, 1995). Therefore, to ensure regulation o f specific genes and to
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enhance DNA-sequence specificity, the Pax transcription factors must engage in
additional interactions with various partner proteins (Hagman et al., 2000).
The transactivation function o f Pax-5 is regulated by the C-terminal regulatory
module comprised o f Ser/Thr/Pro-rich transactivation domain (aa 304-358) and the
adjacent repressor sequence (aa 358-391) (Dorfler and Busslinger, 1996). The inhibitory
domain has been proposed to function as a DNA context-specific “switch” that
determines whether Pax-5 acts as an activator or a repressor of transcription of a
particular gene (Dorfler and Busslinger, 1996). Interestingly, similar negative regulatory
domains appear to be common in inducible transcription factors that are activated by
intracellular signaling events. Although a connection between transcriptional activation
and signal transduction has not been found for Pax-5, it is conceivable that such a link
could have an important function in regulation of gene transcription during B cell
activation.
To date, the exact mechanism of differential regulation o f Pax-5 target genes
remains unclear.

It has been established that regulation of many Pax-5 target genes

requires recruitment and cooperative interactions with partner-proteins (Fitzsimmons et
a l., 1996; Eberhard et al., 2000). Alternatively, transcription of some positively regulated
genes might be initiated through the direct contact between the basal transcription
machinery and Pax-5 functional domains other than the C-terminal regulatory module
(Dorfler and Busslinger, 1996).

The homeodomain homology m otif (aa 229-251) and

the octamer sequence (aa 179-186) are the likely candidates for such interactions, as both
have been shown to be involved in complex formation with other proteins. For example,
the partial homeodomain can bind the TATA-binding (TBP) and the retinoblastoma (Rb)
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proteins (Eberhard and Busslinger, 1999).

Incidentally, the Rb protein is known to

repress activity o f several transcription factors by either inhibiting their interaction with
the basal transcription machinery or by promoting the formation of inactive chromatin
(Weintraub et a l., 1995; Luo et al., 1998).

The octamer sequence is involved in

interaction o f Pax-5 with Groucho proteins which repress Pax-5 transcriptional activity
(Eberhard et a l., 2000).

In addition, the presence o f the octapeptide m otif has been

shown to attenuate transactivation function o f Pax-2 and several other Pax proteins
(Lechner and Dressier, 1996).

2.5 Pax-5 iso forms
The Pax-5 gene produces four alternatively spliced variants: Pax-Sa, Pax-5b,
Pax-5d, and Pax-5e (Figure 1.4; Zwollo et al., 1997). The full length Pax-5 is known as
the B cell-specific transcription factor BSAP, and corresponds to the Pax-5a isoform.
Alternative isoforms o f the Pax-5 gene include transcripts with incomplete DNA-binding
domains (Pax-5b and Pax-5e), and the variants in which a region containing the
homeodomain and the C-terminal regulatory module (aa 203-391) has been replaced with
the novel sequence (Pax-5d and Pax-5e). It has been shown that only the Pax-5a and
Pax-5d isoforms can interact with the Pax-5 binding site (Zwollo et al., 1997). Due to the
deletions in the paired domain, Pax-5b and Pax-5e are unable to bind to DNA and must
regulate their target genes by indirect mechanisms or via interactions with other factors.
At the present, the function o f the novel sequence (aa 203-244) is unknown, but has been
hypothesized to have an inhibitory role in regulation of transcription (Anspach et al.,
submitted).

21
The four Pax-5 isoforms exhibit different levels and patterns of expression
throughout B-cell development and may vary in their function and transactivation
properties. In agreement with previous findings, the levels o f Pax-5a appear to be high
during all stages o f B cell development except the plasma cell stage. Pax-5d levels are
low in B cell lines, but easily detectable in resting splenic B cells (Anspach et a l.,
submitted). Normal resting B cells, as well as early B cell lines, contain very low levels
o f Pax-5e and Pax-5b protein. Curiously, Pax-5b levels increase during the late stages of
B cell development and the protein remains detectable even in the plasma cell line
(Zwollo et al., 1997); however, the significance of this is unclear. The relative levels of
alternative Pax-5 transcripts have been estimated by screening X phage libraries
containing spleen or B cell cDNA from the mature B cell line A20/2J (Zwollo et al.,
1997). In 45 Pax-5-containing clones isolated from the spleen library, 35 represented
isoform Pax-5a (78%), seven clones were Pax-5d (15.6%), two were Pax-5b (4.4%), and
one was identified as Pax-5e (2%) (Zwollo et al., 1997). It is not unlikely that relative
levels o f Pax-5 isoforms vary depending on the developmental stage or activation status
o f B cells.
In addition to alternative splicing, each Pax-5 transcript can produce proteins
from one o f two available translational start sites: a proximal ATG codon (at nucleotide
1) and a distal ATG codon (at nucleotide 325) (Figure 1.4; Zwollo et al., 1997). Use of
the proximal ATG codon generates isoforms Pax-5a and Pax-5d from the corresponding
transcripts.

Translation initiation from the distal codon on either Pax-5a or Pax-5b

transcripts produces a 41-kD protein with a partial DNA-binding domain. Likewise, the
Pax-5e isoform can arise from either Pax-5d or Pax-5e transcript with translation starting
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at the distal ATG start site.

While both Pax-5b and Pax-5e have the proximal ATG

codon, translation from that start site creates a termination codon at nucleotide 245
resulting in the expression o f a short 3.2-kD (27 aa), peptide (Zwollo et al., 1997). The
presence o f two alternative start sites on the Pax-5 transcripts suggests that a single
transcript can give rise to two different proteins. The mechanism controlling the switch
from one start codon to another may have an important role in regulation of differential
expression o f Pax-5 isoforms.

3. Regulation o f transcription factors
3.1 Combinatorial gene regulation
Complex molecular pathways involved in B cell development and function
require cooperation o f multiple transcription factors or “combinatorial regulation” o f the
associated genes (Ernst and Smale, 1995).

The diverse patterns o f regulation are

generated by unique combinations and spatial arrangements o f these factors at the
promoter and enhancer regions o f each specific gene (Chen, 1999). For temporally- and
spatially-regulated gene expression, it is essential for a cell to have a particular set of
factors present at each stage o f the development and differentiation.

Hence, the

expression and activity o f any given factor is tightly regulated by distinct signal
transduction pathways in a stage-specific manner.
Four levels o f regulation determine the concentration and activity o f transcription
factors:

transcriptional,

post-transcriptional,

translational,

and

post-translational

(Calkhoven and Geert, 1996). At the level o f transcription, the frequency o f initiation of
transcription and the rate o f RNA synthesis determine the expression levels of
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transcription factors. At the post-transcriptional level, mRNA stability, transport, and,
most importantly, RNA processing events regulate the amount and diversity of the
synthesized proteins.

At the translational level, the function and availability of a

transcription factor can be affected by selection of alternative start-sites, rate o f protein
synthesis, and by specifics o f nuclear transfer associated with that factor. Finally, protein
function and activity can be controlled post-translationally by structural modifications
and specific interactions with other proteins. In addition, one of the critical factors for
the function o f transcription factors is their stability. Protein stability can be regulated at
any o f the mentioned regulatory levels, its changes often induced by various extracellular
signals (Pahl and Baeuerle,

1996).

Regulatory events occurring at the post-

transcriptional and post-translational levels are especially interesting for the work
presented in this thesis and will be discussed in more detail in the following sections.

3.2 Post-transcriptional control: alternative RN A splicing
Alternative RNA splicing allows generation of families o f transcription factors
with diverse and distinct properties (Foulkes and Sassone-Corsi, 1992; Lopez, 1995;
Calkhoven and Geert, 1996). Originating from a single gene, alternative mRNA variants
may generate polypeptides which differ in their functions, translation efficiency, DNAbinding activity, ability to engage in protein-protein interactions, and stability (Lopez,
1996). The expression levels o f alternative isoforms and their proportions are frequently
regulated according to developmental stage, tissue specificity, or cell polarity (Lopez,
1996). For example, six alternatively spliced isoforms of Pax-8 gene are temporally and
spatially regulated during early mouse development (Kozmik et al., 1993).

Although
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production o f alternative isoforms has been reported for a number o f transcription factors,
the biological consequences and advantages of this phenomenon are not clearly
understood in many cases.
Alterations in a DNA-binding domain may result in synthesis of proteins that
control distinct sets of genes, as a result of a differential capacity for target sequence
binding and recognition. These type o f functional variations can be achieved either by
truncation o f the entire DNA-interaction region, or by generation o f isoforms with a
different number o f DNA-binding domains, different spacing between the motifs, or with
variable specificity. For example, alternative insertion of additional amino acid residues
affects the paired domains o f Pax-6, Pax-3, and Pax-7, resulting in generation o f isoforms
with various DNA-binding potentials and specificities (Kozmik et al., 1997; Vogan et a l.,
1996). Ikaros, a gene implicated in the control of B- and T-lymphopoiesis, produces
eight alternatively spliced isoforms which differ in the number of the N-terminal zinc
fingers (Georgopoulos et al., 1997).

With at least three zinc fingers required for

sequence-specific, high-affinity DNA-binding, only three Ikaros proteins (Ik-1, Ik-2, and
Ik-3) contribute directly to transcriptional regulation of their target genes; others are
transcriptionally inert.
The most common strategy for the production of activator and repressor isoforms
from the same gene involves alterations within the transactivation domain or its complete
removal (Foulkes and Sassone-Corsi, 1992). If such isoforms possess identical DNAbinding domains and have similar binding affinities for target sequences, they can
compete for DNA binding. This provides a mechanism for differential regulation that
depends on the relative concentration of the competing isoforms. The same holds true for
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activators o f different strengths.

For example, Pax-4 and Pax-6 recognize similar

sequences and may compete for binding in tissues with overlapping expression
(Kalousova et al., 1999).

However, because Pax-4 is a weaker activator than Pax-6

(Kalousova et al., 1999), it may actually function as a Pax-6 inhibitor.
Isoforms lacking DNA-binding and/or transactivating domains may exert their
inhibitory function by sequestering other factors into inactive complexes (Lopez, 1996).
For example, non-DNA-binding Ikaros proteins can play a dominant-negative role in
transcription by forming transcriptionally inert heterodimers with active DNA-binding
isoforms (Georgopoulos et al., 1997). Alternatively, the inhibitor-isoforms that contain
functional protein interaction motifs can inhibit transcription by binding accessory and
partner-proteins which are necessary for combinatorial gene regulation.

3.3 Post-translational control: structural protein modifications
Post-translational level o f control involves structural modifications which affect
the activity and functions o f transcription factors.

These modifications may include

(de)phosphorylation, acetylation, glycosylation, formation of disulfide bonds (redox
potential), or any other alterations which may induce conformational changes in a
protein. Through exposing, masking, or remodeling a particular functional domain, posttranslational modifications may determine the DNA-binding activity and transactivation
function o f a transcription factor, as well as its nuclear localization, stability, and
association with other proteins (Calkhoven and Geert, 1996).

Compared to the

transcriptional level o f control, regulation at the protein level is faster and more readily
reversible.

Such functional flexibility is important for a great number o f transcription

27
factors which participate in signal-transduction cascades, including NF- k B, c-Jun, p53
(Calkhoven and Geert, 1996). In that context, post-translational modifications provide a
sensitive mechanism for a quick and efficient response to specific signaling pathways that
lead to activation or inhibition o f particular target genes.
Phosphorylation is one o f the most common means of functional regulation which
affects a wide variety o f cellular proteins, including nuclear transcription factors. Easily
reversible and abundant, phosphorylation frequently occurs as a step in signal
transduction cascades triggered by environmental stress and stimulation o f cell-surface
receptors (Hunter and Karin, 1992; Calkhoven and Geert, 1996). For instance, multi-site
phosphorylation is a major mechanism regulating the activity o f p53 in response to
various extracellular stimuli (Meek, 1998). This modification can modulate a number of
the protein’s functions ranging from DNA-binding and transactivation properties to its
stability and ability to interact with other factors (Lambert et al., 1998; Meek, 1998;
Steegenga et al., 1996). Another example is phosphorylation of c-Jun which is triggered
by mitogenic stimulation and stress. The phosphorylation sites of c-Jun are located in the
transactivation domain, and their modification results in increased transactivation
potential o f this transcription factor (Calkhoven and Geert, 1996).
Modification o f transcription factors via formation o f disulfide bonds has not been
studied as extensively as protein phosphorylation.

However, several recent studies

indicate that modification o f redox state is an important mechanism o f regulation of
transcription factors.

Redox regulation occurs through reduction/oxidation of specific

cysteine residues and formation of disulfide bonds in different functional domains of a
protein (Tell et al., 2000).

The process is mediated by reducing enzymes, such as
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thioredoxin and Ref-1, and is often triggered by oxidative stress (Hirota et al., 1997;
Hirota et al., 1999).

Frequently, modification o f protein redox state is involved in

regulation o f DNA binding activity and, as a rule, reduced forms o f transcription factors
are required for efficient binding to DNA sequences. For example, activity o f NF-kB
(Schreck et al., 1991; Hirota et al., 1999), AP-1 (Abate et al., 1990; Hirota et al., 1997),
HIF-like factor (HLF) (Lando et al., 2000), and Pax-2/5/8 proteins (Tell et al., 1998)
depends upon reduced state o f their DNA-binding domain.

Interestingly, hypoxia-

inducible factor l a (H IF -la), which is closely related to the HLF, does not require the
presence o f reducing enzymes for its DNA-binding; however, its transactivation domain
is subject to redox control by Ref-1 (Lando et al., 2000).

Another facet of redox

regulation involves formation o f an intermolecular disulfide bond in E2A homodimers
(Benezra, 1994), which play an important regulatory role in B lymphocyte development
(Murre et al., 1989).

In monomeric form, the protein has a very low DNA binding

activity, although it can still efficiently heterodimerize with its partner-proteins (Benezra,
1994). Thus, only E2A homodimers can bind to DNA. That interaction is stabilized by a
disulfide link between two E2A proteins (Benezra, 1994), and has recently been shown to
be regulated by redox-active proteins (Markus and Benezra, 1999).
Glycosylation has long been considered a modification that occurs exclusively on
extracellular or lumenal proteins.

Recently, however, it has become clear that

glycoproteins can also be found in the nucleus (reviewed in Haltiwanger et al., 1997;
Comer and Hart, 2000).
glycosylation

affecting

The best characterized and the most abundant type of
transcription

factors

is

glycosylation

by

O-linked

N-

acetylglucosamine (O-GlcNAc) (Haltiwanger et al., 1997). This modification involves
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addition o f a single monosaccharide residue, 0-GlcNAc, to the side-chain hydroxyl
groups o f serine and/or threonine. The enzymes responsible for the addition and removal
o f O-GlcNAc moieties to proteins have been identified (Haltiwanger et al., 1990; Dong
and

Hart,

1994).

A

uridine

diphospho-A-acetylglucosamine:polypeptide

p-AL

acetylglucosaminyltransferase (0-G lcN A c transferase) is a soluble enzyme with a strong
preference for peptides containing a proline residue (Haltiwanger et al., 1997).

O-

GlcNAc transferase has been found in both cytoplasm and nucleus (Haltiwanger et al.,
1992; Kreppel et al., 1997; Akimoto et al., 1999), and its gene was cloned from rat, C.
elegans and human (Kreppel et al, 1997; Lubas et al., 1997). A cytosolic and nuclear pA^-acetylglucosaminidase with selectivity toward O-linked GlcNAc has also been
identified and purified (Dong and Hart, 1994).
About fifty different cytoplasmic and nuclear proteins are known to be modified
by O-glycosylation (Haltiwanger et al., 1997). These include transcription factors Spl
and A pl (Jackson and Tjian, 1988), the tumor suppressor protein p53 (Shaw et al., 1996),
nuclear pore complex proteins (Holt et al., 1987), c-Myc (Chou et al., 1995), and various
cytoskeletal proteins (for references see Haltiwanger et al., 1997).

The levels of

glycosylation may vary for different proteins and during specific signaling events, which
indicates that this modification is dynamic and reversible (Comer and Hart, 2000). Oglycosylation has been hypothesized to play a role in regulation of such processes as cell
activation and cell division (Kearse and Hart,

1991; Chou and Omary,

1993),

transcriptional regulation (Jackson and Tjian, 1988; Kelly et al., 1993; Chou et al., 1995),
and protein synthesis (Datta et al., 1989).
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While a strict consensus sequence has not been discerned for O-GlcNAcmodified proteins, most glycosylated sites contain a proline residue amino-terminal to the
modified serine or threonine (Haltiwanger et al., 1997).

These sites are remarkably

similar to sites phosphorylated by mitogen-activated and other proline-directed kinases
(Kemp and Pearson, 1990). In fact, most O-glycosylated proteins are also extensively
regulated by phosphorylation, which appears to compete with O-GlcNAc for sites on
such proteins (Haltiwanger et al., 1997; Comer and Hart, 2000).

The interrelation

between O-GlcNAc-glycosylation and phosphorylation is complex, and the two
modifications are probably differentially regulated through distinct signaling pathways,
adding infinite diversity to protein function.

4. Significance and goals o f the presented research
4.1 Functional significance o f Pax-5 iso forms
The Pax-5 gene plays a central role in B cell development, activation and
differentiation.

The gene generates at least four alternatively spliced isoforms which

have been identified based on the presence of the intact DNA-binding domain and the Cterminal transactivation domain (Zwollo et al., 1997). The Pax-5a isoform, known as B
cell-specific activator protein (BSAP), is the most extensively studied product encoded
by the Pax-5 gene, and its transactivation function has been investigated on a number of
B cell-specific genes (Hagman et al., 2000). However, the functions and regulatory roles
o f other Pax-5 isoforms are yet to be determined.
Among the Pax-5 proteins, Pax-5a and Pax-5d are o f special interest. These two
isoforms are the most abundant in mature B cells and both have an intact DNA-binding
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domain that enables them to interact with Pax-5-specific DNA-binding sites. The two
isoforms, however, differ dramatically in the composition of their C-terminus.

In

contrast to Pax-5a, Pax-5d does not have transactivation, repression, or partial
homeodomain homology regions, but possesses the novel sequence instead (Zwollo et a l.,
1997). Although the regulatory role o f the novel sequence is not yet known, it is likely to
confer a dominant-negative function to Pax-5d isoform. Thus, it is possible that Pax-5a
and Pax-5d not only compete for binding, but also have opposing effects on transcription.
Consequently, the relative levels o f these two isoforms may determine the expression of
Pax-5 target genes. Furthermore, it can be speculated that the ratio o f the two proteins
might change as B lymphocytes progress through the differentiation stages during their
development and activation.

Such a change may serve as a sensitive switch that

determines a rapid activation or repression o f particular genes during each stage o f B cell
differentiation.
While only Pax-5a and Pax-5d can affect transcription through direct promoterenhancer binding, it is cannot be excluded that Pax-5b and Pax-5e isoforms may also
participate in gene regulation (see Figure 1.4).

Both isoforms possess the octamer

sequence implicated in protein-protein interactions and regulation of the transactivation
function (see Section 2 .4 ).

Furthermore, Pax-5b contains the homeodomain and the

transactivation domain, which have also been shown to play a role in protein-protein
interactions (Eberhard et al., 2000). The presence o f three functional domains capable of
diverse protein-protein interactions indicates that this isoform may participate in gene
regulation as a co-repressor, co-activator, or an inhibitor which sequesters subunits of
transcriptionally active complexes. The same model can be applied to the Pax-5e isoform
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in which the homeodomain and transactivation region are replaced with the novel
sequence.

Hence, while having no DNA-binding activity, the Pax-5b and Pax-5e

isoforms may retain a capacity for protein-protein interactions, which would allow them
to function as dominant-negative variants of Pax-5a and Pax-5d.
Previous studies have shown that the DNA-binding activity o f Pax proteins is
subject to redox regulation due to the presence of three conserved cysteine residues (Cys
37, Cys 49, and Cys 109) within the paired domain (Tell et al., 1998; Tell et al., 2000).
The presence o f the two additional cysteine residues in the novel sequence o f Pax-5d and
Pax-5e presents interesting possibilities for formation o f inter- and intra-molecular
disulfide bonds within individual proteins and between different isoforms o f the Pax-5
family.

These may include generation of Pax-5d/Pax-5e homo- and heterodimers,

regulation o f the novel sequence function via redox-regulated protein folding, as well as
formation of transcriptionally-inert complexes between DNA-binding and non-binding
isoforms. If such interactions indeed occur, various reducing/oxidizing factors, such as
Ref-1, thioredoxin, or reactive oxygen species, may not only affect DNA-binding activity
o f the paired domain, but may also play a key role in the control of transactivation
properties o f Pax-5 proteins.

4.2 Research project: major goals
The study presented here pursued two goals. First, the transactivation properties
o f the Pax-5d isoform were determined in vivo using a transient transfection system.
Evidence is provided indicating that Pax-5d has a function opposite to that o f Pax-5a, and
that the two isoforms may compete for binding to Pax-5 recognition sequences. The ratio
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o f Pax-5a to Pax-5d was, therefore, hypothesized to determine the transcription levels of
Pax-5 target genes.
The second goal o f this project was to investigate the expression patterns o f Pax-5
proteins in resting and LPS-activated B cells. The ratio o f Pax-5 isoforms was analyzed
in activated and non-activated B cell lines and splenic B lymphocytes. In addition, the
DNA-binding activities o f Pax-5a and Pax-5d isoforms were assessed in resting and
activated normal B cells. The experimental data suggests that activation signals induce a
change in the ratio o f different Pax-5 proteins and may trigger specific post-translational
modifications o f the predominant Pax-5a isoform.

4.3 Preliminary studies
In the context of the described research, preliminary investigations were
conducted that included identification of concentration requirements for the proposed
Pax-5a/Pax-5d binding competition, LPS-activation o f B lymphocytes isolated from aged
mice, activation o f the immature B cell line W EHI-231, and initial characterization o f the
novel Pax-5Xspecies. These investigations were designed to provide clarification and/or
additional support for the observations of the project described in the previous section.
More specifically, the goals o f preliminary studies included: a) development o f the
“staggered” transfection

approach for functional

studies o f Pax-5

proteins;

b)

comparative analysis of the expression patterns of Pax-5 proteins in young and aged B
lymphocytes activated by mitogenic stimulation; c) determination of the ratio o f Pax-5
proteins in LPS-activated B cell line W EHI-231; and d) demonstration o f a link between
Pax-5e isoform and the novel Pax-5Xspecies.
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Sum m ary o f specific research aims

1. Determination o f transactivation properties o f isoform Pax-5 cl.
aspects o f Pax-5a and Pax-5d DNA-binding competition.

Functional

Non-lymphoid cell

lines, NIH 3T3 and COS-1, were transiently co-transfected with different
combinations o f the Pax-5a and/or Pax-5d effector constructs and an artificial
promoter reporter construct that contained three high-affinity Pax-5 DNA-binding
site from the murine CD 19 promoter.

The transactivating effect o f individual

isoforms or their combinations was estimated based on the expression of a
chloramphenicol acetyltransferase (CAT) reporter gene.

2. Analyses o f Pax-5 proteins in LPS-activated mature B lymphocytes.

Mature

resting B cells were isolated from spleens of young mice and activated by
treatment with bacterial lipopolysaccharide (LPS). Nuclear extracts isolated from
resting and activated B cells were assayed for Pax-5 proteins' levels and
expression patterns using Western blot analysis. DNA-binding activity o f Pax-5a
and Pax-5d proteins was determined in nuclear extracts o f resting and LPSactivated primary B lymphocytes using electrophoretic mobility shift assay
(EMSA).

3. Analyses o f Pax-5 proteins in B cell lines.

The protein levels, expression

patterns, and the ratio of Pax-5 isoforms were analyzed in B cell lines
representing different stages of B cell differentiation using Western blot analysis.
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The immature B cell line W EHI-231 was activated by either surface IgM crosslinking or through mitogenic stimulation.

Nuclear extracts from activated and

non-activated cells were assayed for expression patterns and DNA-binding
activity o f the Pax-5 isoforms using Western blot analyses and EMSA.

4. Analyses o f the Pax-5 proteins in LPS-activated B lymphocytes isolated fr o m
aged mice. Mature resting B cells were isolated from spleens of aged mice and
activated by treatment with LPS.

Nuclear extracts isolated from resting and

activated B cells were assayed for Pax-5 proteins’ levels, expression patterns, and
DNA-binding activity using Western blot analysis and EMSA. The results were
compared with data obtained for young mice (Aim 2).

5.

D evelopm ent o f a “staggered” transfection system.

A novel transient co

transfection approach was used for detailed examination of Pax-5a/Pax-5d DNAbinding competition requirements.

6. Characterization o f the novel Pax-5x species. Non-lymphoid cell line NIH 3T3
was transiently transfected with Pax-5e and Pax-5d expression constructs.
Nuclear extracts from the transfected cells were analyzed by Western blot to
determine the nature of the Pax-5Xband.
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Chapter II
Functional Analyses of Alternative Isoforms of the
Trancription Factor Pax-5.
M arina Lowen and Patty Zwollo
The College o f William and Mary, Williamsburg, VA 23187
M anuscript in preparation

A BSTR A C T
The Pax-5 gene plays a central role in B cell development, activation and
differentiation. At least four different isoforms have been identified. Isoform Pax-5a,
known as B cell-specific activator protein (BSAP), is the most extensively studied gene
product and its regulatory functions have been investigated for a number of B cellspecific genes. However, potential functions for other Pax-5 isoforms have not yet been
reported.

In the studies described here, we demonstrate that Pax-5d has a function

opposite to that o f Pax-5a and, hence, acts as a transcriptional inhibitor o f a basal
promoter CAT construct containing three Pax-5 binding sites.

Furthermore, Pax-5d

represses activity o f Pax-5 a when the two isoforms are expressed simultaneously,
suggesting that the ratio o f Pax-5 a and Pax-5d protein in the nucleus modulates
transcriptional activation o f target genes.

Comparison o f resting and LPS-activated

mature B lymphocytes as well as B cell lines representing various stages o f B cell
differentiation, revealed the presence of an unidentified Pax-5 species, Pax-5X, during the
late stages o f activation. The Pax-5a/Pax-5x ratio decreases as mature B cells become
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activated, and we hypothesize that the Pax-5X species acts as a repressor o f Pax-5a
activity.

Moreover, LPS-activation induces post-translational modifications at the C-

terminus o f Pax-5a affecting the C-terminal repressor domain.

Together, our

observations suggest that during activation and differentiation of B lymphocytes, Pax-5a
function changes, and this is accomplished through post-translational mechanisms as well
as through upregulation o f the repressor isoforms.

IN TR O D U C TIO N
B lymphocytes are the major players of the humoral immune system and are
essential to the detection and elimination of pathogens.

Their main distinguishing

characteristic is the ability to synthesize and secrete specific immunoglobulin (Ig)
molecules in response to pathogens. Activation o f mature B cells in vitro may either be
induced by antibody cross-linking o f the B cell antigen receptor complex, or through
stimulation

by

specific

cytokines

and/or

B

cell

mitogens

such

as

bacterial

lipopolysaccharide (LPS). Activation signals trigger a cascade o f events that result in
proliferation, further differentiation o f mature B lymphocytes into plasma cells, and Ig
secretion (Reya and Grosschedl, 1998).
Spatial and temporal gene expression of B cell-specific transcription factors
largely determines the maturation and activation pathways in a B cell, and is a tightly
regulated process. Gene expression o f transcription factors can be controlled at multiple
levels including transcription initiation, alternative RNA splicing, mRNA stability, and
translation efficiency (Calkhoven and Geert, 1996). In addition, activity o f transcription

factors can be regulated at the post-translational level and may involve phosphorylation,
acetylation, proteolysis, and/or regulation of the redox state (Hunter and Karin, 1992;
Pahl and Baeuerle, 1996; Calkhoven and Geert, 1996). Post-translational modifications
may regulate the DNA-binding activity and transactivation function o f a transcription
factor, as well as its nuclear localization, stability, and association with other proteins
(Calkhoven and Geert, 1996). Modifications o f already-expressed transcription factors
provide a sensitive and efficient mechanism, allowing for rapid responses to specific
signaling pathways during cell differentiation or activation.
A number o f transcription factors have now been identified as essential for B cell
development and activation (reviewed in Reya and Grosschedl, 1998; Liberg and
Sigvardsson, 1999). Among these factors are the products encoded by the Pax-5 gene
which include one o f the most critical transcription regulators, the B-cell specific
activator protein (BSAP).

Pax-5 is a member o f a family o f genes involved in

development, morphogenesis, and pattern formation (Strachan and Read, 1994; Stuart
and Gruss, 1995). The Pax family consists o f nine members {Pax-1 through Pax-9) all of
which share an evolutionarily conserved N-terminal DNA-binding region comprising the
paired domain (Walther et a l., 1991). The family o f Pax proteins is divided into four
subclasses based on the presence or absence of specific domains (Adams et a l., 1992).
Pax-5 expression is first detected in the developing central nervous system
(Adams et a l., 1992; Asano and Gruss, 1991). After birth and throughout life, Pax-5
transcripts are found in cells o f the B-lymphoid lineage and in adult testis of the mouse
(Adams et a l., 1992). Inactivation o f the Pax-5 gene in mouse results in a complete block
o f B cell development at the pro-B cell stage, revealing the essential role o f this gene in
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early B cell lymphopoiesis (Urbanek et al., 1994). Within the B cell lineage, Pax-5 is
expressed during early stages o f B cell development up to the mature B-cell, but is
greatly downregulated or absent in plasma cells (Barberis et al., 1990).
Pax-5 binding sites have been identified on the promoters o f a number o f B-cellspecific genes (reviewed in Hagman et al., 2000). Among the positively regulated Pax-5
targets are genes encoding the CD 19 co-stimulatory receptor (Kozmik et al., 1992) and
the protein tyrosine kinase Blk (Zwollo and Desiderio, 1994).

Pax-5 functions as a

repressor for the immunoglobulin J chain and the Ig 3’a enhancer (Rinkenberger et al.,
1996; Singh and Birshtein, 1993; Neurath et al., 1994).

In addition to its role in B-

lymphopoiesis, Pax-5 has been implicated in activation and proliferation of B
lymphocytes since its decreased expression resulted in reduced numbers o f cells post
activation (Wakatsuki et al., 1994).

However, terminal differentiation o f mature

activated B cells into plasma cells that are capable o f Ig isotype class switching and high
antibody production may require downregulation of Pax-5 activity (Usui et al., 1997;
Cogne et al., 1994; Stuber et al., 1995).
The Pax-5 gene produces four isoforms as a result of alternative splicing: Pax-5a
(full length Pax-5 or BSAP), Pax-5b, Pax-5d, and Pax-5e (Zwollo et al., 1997) (Figure
II. 1). O f those, only Pax-5a and Pax-5d isoforms are expressed at readily detectable
levels in resting B cells, although the levels o f Pax-5d transcripts are lower than those of
Pax-5a (Anspach et al., submitted). Both Pax-5a and Pax-5d, but not Pax-5b or 5e, have
an intact DNA-binding domain, enabling them to interact with and compete for Pax-5binding sites on DNA in vitro (Figure 1; Zwollo et al., 1997). However, in contrast to

o

N
T

■o
io
I
X
C
3
Q
h

.£
<
03 l~7r
03
CD

E
o3

Q
O DC

ID

42
ir>

■r>

a
Ph

2-

2-

O
D
m
><
a
P4

_

33
.o o 5 u o
e -O '5b
D
x
s—
I § C
03
Oh
CD CD M
)
P
*3 _o
■(-* 03
O
a
CD 7 3
£
o
.33

I

rn
t

J-

_g
£
£
O
Q
> t3
~
C
3
o
CD
~§ -33 £
■ ^2
co

CD

-33^'~CD

CD
J33

C33 CD

33 C
D
•—C
D
C
D 33
> <
D
03 33
-33 C
T

_>> . c

<
u£

> £
'-32 O

03 73
£ t>j) O n X O
C
D
B .5 (N 03 c/} -33
03 ~0 C
3^ U
D
* 33
»- .£ ■3s~0 £. <
‘O O
33 -Q —5 C
O
o > 33 o3 LhD333 "o
«co </ .2 X) U < °
Cn -33
aj £3 dJ)
<*D 1
O
B
X
/—
Nf—
o3
=
£
73
T
3
X
>
C
D
3
<
o cd Si)
H
8O-1h .—
O—
o3
(3 22 ^-3
"■C3 t o
'o

c
’1 §3
33
o'

O£
£
5
G
! i !
o ^

"3cd
3 73

B
bl)

>

o
:z

C
D
S
_O
C
DC
33 C
D

BO <
§D
■

^3 ^
-x CN
cn
o
C
D CD
-S3 7
3

C
-M
O
3
3
33 O

££3

CD

-33
H

O^

33
O

33
C
D
33
cr

CD ■

o
H

<

o
H<

o
H -4

<

33

O
-C
D
"33 X £>
O ^3
D
^3 ~Q C
a "^3 B3
C
D
C
Sq •S'
xD
•sT
33 C
so X
*> o
jO <5
"a ^

lo3 ! O

OhQ

X
C
5
CD

o
H

<

O

H

<

33 (5
^
O -s
o
C2 C
-X £
33 73
33 33
D-h
o3
O^

73

a
E
—
•
<

S3

O

£3 s7
7 •*
—
*
03

i£

,— v C3

^ ^
22
''t

8

rO
n O
r7

C
N£
—
.
co ■
<
!

CD

o3

____

&

03

Q U7
C
Do
s_
M'O Xi c
33 C
D
03 cr
^
X I ^ CD C
D
03
c
o
7
D
C
D
D
33 <
D”C
3
73 V
O O
O
>
'-P
33 O
V
O
03 O c
<D
~) T
V3
3O
C D
<3\ 7 f X
r- o cd
cn C
D£ I

41
Pax-5a, Pax-5d does not possess transactivation, repression, or partial homeodomain
homology regions at the C-terminus. The region encoded by exons six through ten is
replaced in isoform Pax-5d with a 42 amino-acid novel sequence (Zwollo et al., 1997).
The role o f this sequence is unknown, but it is likely to confer a dominant negative
function to Pax-5d protein.

Isoform Pax-5e has only a partial DNA binding domain,

lacks exons 6 through 10, and shares the same novel C-terminal sequence as Pax-5d
(Figure II. 1). Based on the DNA binding abilities and expression pattern o f Pax-5a and
5d, we hypothesize that the two isoforms compete for binding and have opposite effects
on transcription o f target genes in vivo. Consequently, the relative levels o f these two
isoforms in the nucleus may regulate expression of target genes.
Although a number o f studies have shown clear functional significance o f isoform
Pax-5a (BSAP) (Zwollo et al., 1998; Kozmik et al., 1992; Fitzsimmons et al., 1996), no
work has yet characterized the function of isoform Pax-5d. Thus the first goal of our
studies was to determine the transactivation properties o f Pax-5d. Here we show, using a
transient transfection system, that Pax-5d has a function opposite to that o f Pax-5a.
These results are in agreement with the hypothesis that the ratio of Pax-5a to Pax-5d
affects transcription o f Pax-5 target genes.
Our second goal was to investigate the regulatory function of Pax-5a and Pax-5d
isoforms in LPS-activated, normal B cells.

Our experimental data suggest that LPS-

activation signals induce significant changes at the protein, but not RNA, level o f both
isoforms.

Unexpectedly, we found that LPS activation resulted in a loss o f Pax-5d

protein concomitant with a dramatic increase in the levels of a novel species Pax-5x
during the late stages o f activation. Finally, comparison o f resting and LPS-activated B
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lymphocytes revealed the induction o f a slower migrating Pax-5a species which differed
in the structure o f the C-terminus.

We hypothesize that activation o f B-cells triggers

post-translational protein modification(s) that allow stabilization of Pax-5a and prevent
the removal o f the C-terminal repressor domain.
In summary, data presented here suggest that during B cell activation, the
transcriptional activity o f Pax-5a may be regulated through sensitive post-translational
mechanisms that either inhibit Pax-5a function directly, and/ or through upregulation of
the repressor isoform(s).

M A TER IA LS AND M ETH O DS
Cell Lines. Murine B-lymphoid cell lines KEFTL-1-(pro-B), HAFTL-1 (pro-B),
PD31 (pre-B), 70Z/3 (pre-B), A20/2J (mature B), B17.10 (mature), and C H I2 (presecretor B) were gifts from Dr. Steve Desiderio (The Johns Hopkins University School of
Medicine, MD).

WEHI-231 (immature B), 2PK3 (mature B), and Sp2/0 (plasma cell)

cell lines were purchased through ATCC.

Cells were grown in RPMI-1640 medium

supplemented with 10% fetal bovine serum (Bio-Whitaker, Inc.), 2 mM glutamine, 50
units/ml penicillin, 50 pg/ml streptomycin, and 50 mM P-mercaptoethanol. The COS-1
cell line (ATCC), a transformed African green monkey kidney cell line, was maintained
in DMEM medium containing 10% fetal bovine serum, 2 mM glutamine, 50 units/ml
penicillin, and 50 pg/ml streptomycin. NIH 3T3 (ATCC), an embryonic mouse fibroblast
cell line, was grown in DMEM medium supplemented with 10% calf serum (Gibco BRL
Life Technology), 2 mM glutamine, 50 units/ml penicillin, and 50 pg/ml streptomycin.
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DNA Constructs. The construction o f the p(-191)b//:CAT2mE reporter construct
has been described elsewhere (Zwollo and Desiderio, 1994). This construct contains the
murine blk promoter (nucleotides —191 to +134) that drives expression of the
chloramphenicol acetyltransferase (CAT) coding region, and two copies o f the intronic Ig
pE downstream o f CAT. The y42(3i)AS-CAT reporter construct was created using the
py42CassI CAT reporter (Wallin et al., 1998) (Figure II.2A).

Expression o f CAT is

driven by the truncated rat y-fibrinogen promoter (-54 to +36), which includes a TATA
box and a single Sp-1 binding site. Three copies o f the high-affmity Pax-5 binding site
from the CD19 promoter (5’-CAGACACCCATGGTTGAGTGCCCTCCAG-3’) were
inserted into the polylinker upstream of the y42-fibrinogen promoter.

Recombinant

constructs were sequenced to determine copy number and orientation of Pax-5 binding
sites. The effector constructs pcDNA5a and pcDNA5d were made by cloning the fulllength cDNA sequences o f either Pax-5a or Pax-5d isoform into Notl restriction sites of
the expression vector pcDNA3 (Invitrogen).

The pcDNA3 construct was used as a

negative control effector construct, and the HBIICAT construct (Zwollo and Desiderio,
1994) was used as a control for transfection efficiency.
Transient

Transfections

and

Chloramphenicol Acetyltransferase

Assay.

Transient transfections o f A20/2J, PD31, and 703/Z B cell lines were performed by either
the DEAE-dextran (Grosschedl and Baltimore, 1985) or SuperFect (Qiagen) method.
Non-lymphoid

cell

lines

COS-1

and

NIH

3T3

were

transfected

LipofectAM INE.Plus (Gibco BRL) according to the manufacturer’s protocols.

using
For B-

lymphoid cell lines, 1X106 (SuperFect) or 2X107 (DEAE-dextran) cells in logarithmic
growth phase were transfected with 3-5 pg of total plasmid DNA. Non-lymphoid cell
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lines were transfected with 1-6 jag of total plasmid DNA. Cell extracts were prepared 4348 hr after transfection and assayed for CAT activity as described previously (Lansford et
a l., 1992).

Briefly, cell extracts containing the same amount of total protein were

combined (in a 150 pi volume) with the reaction mixture containing 470 mM Tris, pH
8.0, 3.3 nM 14C-chloramphenicol (Amersham Pharmacia Biotech), and 0.5 mM acetyl
CoA (Sigma). Following 5-8 hr incubation at 37°C, the samples were extracted with 500
pi ethyl acetate and the organic phase was collected and concentrated on a vacuum
centrifuge (SpeedVac® Plus, Savant). The reaction products were chromatographically
separated on a silica gel plate (EM Science) using a chlorophorm-methanol (95:5)
mixture.

The plate was exposed to a Kodak X-OMAT-AR film for 2-10 days.

The

obtained data were quantified using an NIH Image software analysis program
(w w w :http://rsb.ihfo.nih.gov/nih-image/).
determined

by

chloramphenicol

calculating
as

the

follows:

ratio
%CAT

The

of values

relative
for

CAT

acetylated

conversion
and

was

uncetylated

conversion=[Acetylated-M ock]/[(Acetylated-

Mock)+(Unacetylated-Mock)], where “Mock” is the activity o f the mock (transfection
without DNA) transfection.

The values were normalized to the maximum value of

relative CAT conversion within each experiment set at 100%. Protein concentration of
cell lysates was determined by the Bradford assay (Bio Rad Laboratories).
Isolation o f Cell Fractions and Activation o f Sm all Resting B Cells. Splenic B
cells were obtained from 3-6 months old BALB/c mice (bred at The College o f William
and Mary). Teased spleen suspensions from BALB/c mice were collected through a 40
pm nylon cell strainer in complete RPMI-1640 medium supplemented as described
above, washed and re-suspended in Hank’s balanced salt solution. Small resting B cells
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(SRBs) were isolated from a 70% Percoll gradient (Amersham Pharmacia Biotech)
according to the manufacturer’s instructions and re-suspended in complete RPMI-1640
medium at l x l 0 7 cells per ml. The 70% Percoll layer contained approximately 25% T
cells; however, the complement lysis purification step was omitted due to possibility of
partial activation o f B cells by reactions with anti-Thy.l, anti-CD4, and anti-CD8
«

•

(Zwollo, unpublished observations).

Approximately 10

7

cells from the obtained

population were processed immediately to obtain nuclear extracts (as described below).
The remainder o f the population was activated by culturing in complete RPMI-1640
medium

(supplemented

as

above)

in

the

presence

of

20

pg/ml

bacterial

lipopolysaccharide (LPS) (Sigma) for the required period.
N uclear Extract Preparation.

Cells were collected at specified times and

processed for nuclear extracts as described elsewhere (Wallin et al., 1999). Briefly, 106107 cells were treated with lysis buffer (200 pi) containing 10 mM HEPES, pH 7.9, 10
mM KC1, 0.1 mM EDTA, pH 8.0, and 0.4% Nonidet P40. Following 15 min incubation,
the cytoplasmic fractions were collected, and the nuclear pellet was resuspended in 100
pi extraction buffer (20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA, pH 8.0) and
incubated with agitation for 15 min. Nuclear extract aliquots (10 pi) were collected and
stored at -80°C. All buffers contained the following mixture o f protease inhibitors: 0.5
nM phenylmethylsulphonyl fluoride, 0.5 mM dithiothreitol, aprotinin (10 units/ml),
leupeptin (5 mg/ml), and pepstatin A (5 mg/ml).

Procedures for nuclear extract

preparation were carried out on ice in a cold room at 6°C. Total protein concentrations
were determined by the Bradford assay (Bio-Rad Laboratories) according to the
supplier’s recommendations.
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RNA Isolation and RNase Protection Assay. Total cellular RNA was isolated
from Percoll-purifled SRBs or LPS-activated B cells using an RNeasy mini kit (Qiagen)
according to the manufacturer’s instructions.

Anti-sense radiolabeled probes were

prepared as described (Zwollo et al., 1997). Briefly, the plasmid pBS-10.1, containing
the complete Pax-5d sequence, was linearized using the restriction enzyme BsrFl and
transcribed using T7 RNA polymerase in the presence of [a-j2P]-CTP (800 Ci/mmol).
The resulting anti-sense Pax-5 riboprobe 10.1 contained exons 4 and 5 (nts 447-607) plus
the novel sequence o f Pax-5d (nts 608-735), and was used for detection o f the Pax-5a
and Pax-5d transcripts. A (3-tubulin-specific probe was similarly synthesized from the
Bam Hl-linearized form o f the plasmid p// 5, which contains nucleotides 170-263 of the
murine P-tubulin gene. RNase protection assays were performed as described (Zwollo et
a l., 1997). For each sample, the RNA probe (5x10' cpm) was annealed to 1-5 pg o f total
cellular RNA for 5 hr at 55°C. After digestion with RNAse A (40 pg/ml) and RNAse T1
(2 pg/ml) for 30 min at 15°C, proteinase K and sodium dodecyl sulfate were added to 150
pg/ml and 1%, respectively, and the reactions were incubated for additional 15 min at
37°C. Products were extracted with phenol/chloroform, precipitated with ethanol in the
presence o f 10 pg o f tRNA, and resuspended in sample buffer containing 80%
formamide. Products were fractionated by electrophoresis on a 5% polyacrylamide gel
containing 7M urea and detected by autoradiography.

Radioactive RNA size markers

were prepared using linearized pBluescript vectors and T3 and T7 RNA polymerases,
which resulted in labeled RNA transcripts ranging in size form 50 to 291 nucleotides.
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To obtain an optimal internal control, the riboprobe 10.1 and a p-tubulin-specific probe
were incubated simultaneously with each RNA sample.
Western B lot Analysis. Nuclear extracts and cytoplasmic fractions from SRBs,
LPS-activated B cells, or cell lines were separated on

12% denaturing SDS-

polyacrylamide gels and electrophoretically transferred onto nitrocellulose filters
(Schleicher and Schuell) as described previously (Zwollo et a l., 1998). Antibody probing
was performed as described previously (Zwollo et al., 1998). Filters were first incubated
with 1 hr in blocking solution (5% milk in PBS), followed by a 1-2 hr incubation with a
primary antibody in blocking solution (Table I). Next, filters were incubated for 1 hr
with a horseradish peroxidase-conjugated secondary antibody in blocking solution (see
next section). Filters were developed with an enhanced chemiluminescence kit (ECL,
Amersham Pharmacia Biotech), and bands visualized on Eastman Kodak X-OM AT-AR
film.

The density o f Pax-5a and Pax-5d bands was quantified using an NIH Image

software analysis program fwww:http://rsb.ihfo.nih.gov/nih-image/).
A n ti-P a x Antibodies.

Information about isotype-specific Pax-5 antibodies used

in this study is summarized in Table I.

Pax-5d/Pax-5e-specific mouse monoclonal

antibody 6G11, recognizing the C-terminal “novel” sequence, was generated in our lab
(Anspach et al., submitted). 6G 11 supernatants were used at a 1:30 dilution and detected
with a horseradish peroxidase-conjugated goat-anti-mouse IgG secondary antibody
(Zymed). ED-1 antiserum (Zwollo et a l., 1998) was used at a 1:2000 dilution. Pax-5/N19 and Pax-5/C-20 were used at a 1:400 dilution and detected with a horseradish
peroxidase-conjugated rabbit anti-goat IgG (Zymed). OC-1 was used at 1:1000. Rabbit
polyclonal antiserum to the transcription factor TFIID (Santa Cruz Biotechnology) was
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used at a dilution 1:200. The ED-1, OC-1, and anti-TFIID antibodies were detected with
a

horseradish

peroxidase-conjugated

donkey-anti-rabbit

IgG

secondary

antibody

(Amersham Pharmacia Biotech).

Table 1: List of antibodies used in the protein studies.

Type

A ntibody

Source or
R eference
Santa Cruz
Biotechnology

Rabbit
polyclonal

anti-TFIID

N -19

Rabbit
polyclonal
M ouse
m onoclonal
G oat polyclonal

Zw ollo et al .,
1998
A nspach et al .,
subm itted
Santa Cruz
B iotechnology

C-20

G oat polyclonal

Santa Cruz
B iotechnology

OC-1

Rabbit
polyclonal

Zw ollo et al .,
1997

ED-1
6G11

Specificity
N -term inal
dom ain o f TFIID
(TBP) p36
Paired dom ain
aa 13-159
Novel sequence
aa 218-235
N -term inal
dom ain o f Pax-5
aa 2-20
C-term inal
dom ain o f Pax-5
aa 370-391
Hom eodom ain
hom ology region
aa 234-255

R ecognized
Proteins
TFIID (TB P) p36

Pax-5a, Pax-5b,
Pax-5d, Pax-5e
Pax-5d, Pax-5e
Pax-5 a, Pax-5 d

Pax-5a, Pax-5b

Pax-5a, Pax-5b

Electrophoretic M obility S h ift Assays. Standard binding assays were carried out
for 20 min at 30°C in 10-15 pi reactions containing 60 mM KC1, 12 mM HEPES, pH 7.9,
4 mM Tris-Cl, pH 7.9, 1 mM EDTA, 1 mM DTT, 30 ng of BSA, 12% glycerol, 1 pg o f
nuclear extract, 2-4 fmol o f
Desiderio,

1994).

P-labeled DNA probe, and 2 pg poly(dl-dC) (Zwollo and

The double-stranded oligonucleotide CD19/BSAP probe (5’-

CAGACACCCATGGTTGAGTGCCCTCCAG-3 ’) was labeled with [32P]cc-dCTP as
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described previously (Zwollo and Desiderio, 1994).

The ratio of nuclear extract to

poly(dhdC) (in pg) was kept constant at 1:2 in all experiments.

In antibody

supershift/competition EMSAs, nuclear extracts were pre-incubated in the presence o f 1
pi o f antibody without the probe for 10 min at 30°C.

Products were separated by

electrophoresis on 5% non-denaturing polyacrylamide gel in buffer containing 33 mM
Tris-HCl, 33 mM boric acid, and 0.74 mM EDTA.

Gels were dried and exposed to

Eastman Kodak X-OMAT-AR film.
In vitro Transcription and Translation o f Pax-5 Isofornts.

The plasmids

(pBluescript) containing the isoform Pax-5a (pBS.1.2) or Pax-5d (pBS.10.1) were
transcribed in sense direction with T3 or T7 RNA polymerase respectively, as described
previously (Zwollo et al., 1997). Translation was carried out using rabbit reticulocyte
lysate (TnT; Promega) according to the manufacturer's directions.

R ESU LTS
Functional analysis of Pax-5d in vivo.
The transactivation function o f isoform Pax-5a had previously been investigated
in our lab using the blk promoter as the target sequence (Zwollo et a l., 1998). However,
the regulatory role o f Pax-5d is not yet understood.

To determine the transactivation

properties o f isoform Pax-5d in vivo, we initially used a blkCAT reporter construct (191blkCAT2mE) that contains 325 nt o f blk promoter sequence driving expression o f the
CAT reporter gene (Zwollo and Desiderio, 1994). The expression o f the blk gene is
similar to that o f Pax-5 in cells of the B-lymphoid lineage and has been shown to be
positively regulated by Pax-5a (Dymecky et al., 1992; Zwollo and Desiderio, 1994).
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Transient co-transfections with DEAE-dextran were performed in the B cell lines
A20/2J, 70Z/3 and PD31, and the non-lymphoid cell line COS-1, using the blkC A T
reporter construct and different combinations of Pax-5a and Pax-5d effector constructs,
pcDNA5a and pcDNASd, respectively. Due to low transfection efficiency in B cell lines
combined with low activity o f the blk promoter (Zwollo and Desiderio, 1994), we were
unable to determine reliable quantitative differences between experimental samples. As
an alternative approach, we created an artificial promoter containing high affinity Pax-5
DNA binding sites.

Dorfler and Busslinger (1996) had previously used an artificial

promoter system containing three Pax-5 binding sites 5’ o f the TATA box o f the p-globin
gene, and showed that this provides an excellent system for assessment o f Pax-5
regulatory activity.

Three copies o f a double-stranded oligonucleotide containing the

Pax-5 DNA binding site from the murine CD 19 promoter were cloned in sense or anti
sense orientation upstream o f the TATA element o f the truncated rat y42-f!brinogen
promoter driving expression o f the CAT gene.

Both sense and anti-sense reporters gave

similar promoter activities and the anti-sense construct, named y42(3i)AS-CAT, was used
in all subsequent experiments (Figure II.2A).
To verify that the reporter construct y42(3i)AS-CAT was expressed in the
presence, but not absence, o f endogenous Pax-5 protein, transfections were performed in
the mature B cell line A20/2J and the plasma cell line SP2/0.

As expected, CAT

expression was detected in the Pax-5 positive A20/2J line, but not in the Pax-5 negative
SP2/0 line (result not shown). Because of low transfection efficiencies in B cell lines,
subsequent analysis was carried out in two highly transfectable, non-lymphoid cell lines,
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TATA
Pax-5

Pax-5

CAT

Pax-5

-54

+36

y-fibrinogen promoter

y42(3i)AS-CAT

Figure II.2A: The y42(3i)AS-CAT reporter construct. The y42(3i)AS-CAT
reporter construct used for transient transfections contains three copies o f the
high-affmity Pax-5 binding site form the murine CD 19 promoter (Kozmik et al
1992) inserted in anti-sense orientation upstream of the TATA element o f the rat
y-fibrinogen promoter driving the expression o f the CAT gene.
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COS-1 and NIH 3T3.

In all experiments, a pcDNA3 vector without insert was used as a

negative control and was also added to some o f the samples to maintain equal amounts of
transfected DNA per sample. The HBIICAT construct, which drives high and ubiquitous
CAT expression, was used to evaluate transfection efficiency within each experiment
(Zwollo and Desiderio, 1994).
Co-transfections o f y42(3i)AS-CAT with the effector constructs expressing Pax5a or Pax-5d were first performed in NIH 3T3 cells. The reporter gene was expressed at
high levels in the presence, but not absence, of Pax-5a (Figure II.2B) confirming a
positive transactivating function of this isoform in the regulation o f an artificial promoter
construct. In contrast, isoform Pax-5d was unable to activate the reporter gene, yielding
only basal levels o f transcription that were similar to those produced in the presence of
the control plasmid pcDNA3 (Figure II.2B).
Next, we used the COS-1 cell line to further assess Pax-5d function.

COS-1 cells

do not express Pax-5, but since they are derived from kidney cells, they express the
closely related Pax -8 protein. Both Pax-5 and Pax -8 belong to the same subclass of Pax
proteins and both recognize the Pax-5 DNA binding sequence from the human CD 19
promoter (Walther et al., 1991; Kozmik et al., 1993). We first confirmed the presence of
Pax -8 in COS-1 cells by EMSA using the CD19/BSAP probe and a variety of anti-Pax
antibodies (Table I). We were able to show that the upper protein-DNA complex, which
was expected to contain Pax- 8 , was absent in the presence o f anti-paired domain
antiserum Ed-1, and reduced using the OC-1 antiserum (Figure II.2C). The latter is due
to partial sequence homology within this region between Pax-5 and Pax -8 (Kozmik et al.,
1993). In contrast, two Pax-5-specific antibodies, Pax-5/N-19 and Pax-5/C-20, were
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Figure II.2B: Activation of the reporter gene by exogenous Pax-5. The
y42(3i)AS-CAT reporter construct (lp g ) was transiently co-transfected
with various effector constructs (2pg) into NIH 3T3 cell line, as indicated.
HBIICAT construct was used to evaluate transfection efficiency. The
pcDNA3 expression vector was used as a negative control. Percent
conversion o f unacetylated to acetylated chloramphenicol was normalized
to the value for HBIICAT transfection set at 100%. This chart represents
a single experiment with 3 pg of total transfected DNA.
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Pax-8specific
complexes

Figure II.2C: EMSA of nuclear extracts from non-lymphoid cell line COS-1.
COS-1 nuclear extracts (1 pg) were assayed for the presence of Pax -8 protein by
EM SA using the CD19/BSAP probe. Prior to assay, the samples were pre
incubated with antibodies directed against various regions of Pax-5 (see Table I).
Lane 1: ivt Pax-5a ( lp l lysate) and ivt Pax-5d (2 pi lysate); lane 2: COS-1 nuclear
extract; lane 3: COS-l+ED-1 (anti-paired domain antibody); lane 4: COS-l+OC-1
(homeodomain-specific antibody); lane 5: CO S-l+N-19 (Pax-5 N-terminus-specific
antibody); lane 6 : CO S-l+C-20 (Pax-5 C-terminus-specific antibody), ivt, in vitro
translated protein.
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unable to remove the complex. Together, the data provided the necessary evidence to
confirm that COS-1 cells express Pax- 8 .
Because o f the similarities in specificity o f Pax-5 and Pax- 8 , the COS-1 cell line
provided a useful tool for examination of inhibitory and/or competition functions of
isoform Pax-5d.

First, endogenous Pax -8 was able to transactivate CAT reporter

expression in COS-1 cells in the absence of Pax-5 effector constructs (Figure II.3A,
pcDNA alone). Second, when increasing amounts o f the Pax-5d effector construct were
co-transfected, a dose-dependent decrease in CAT activity was observed (Figure II.3A).
Addition o f increasing amounts of pcDNA5d DNA correlated with the increase in the
levels o f expressed Pax-5d proteins, as determined by Western blot analysis o f the
transfected samples (Figure II.3C).

In contrast, adding increasing amounts o f Pax-5a did

not have a significant effect on promoter activity, possibly because endogenous Pax -8
already has a saturating transactivating effect on the reporter (result not shown).
To confirm an activating role for Pax-5a, the y42(3i)AS-CAT construct was co
transfected with increasing amounts o f Pax-5a construct in the NIH 3T3 cell line, and this
resulted in increased CAT activity (Figure II.3B).

In this system, increasing amounts of

the transfected DNA also correlated with an increase in the levels of corresponding
proteins (result not shown). Together, these results show that isoform Pax-5d, but not
Pax-5a, is able to suppress activity o f a Pax-5 sensitive promoter.
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Figure II.3A: Pax-5a and Pax-5d have opposite effect on transcription:
Pax-5d inhibits transcription of the reporter gene. The y42(3i)AS-CAT
reporter construct (0.5 pg) was transiently co-transfected with various
concentrations o f the pcDNA5d effector construct into COS-1 cell line. The
concentrations o f the pcDNA5d construct (in pg) are designated at bottom
o f the chart. In each experiment, a pcDNA3 vector without insert was used
as a negative control and added to maintain equal amounts of transfected
DNA in each sample. Error bars show the mean ± S.E. (n=3). Percent CAT
conversion was determined as described in “Materials and M ethods” and
normalized to the maximum percent conversion value within each
experiment.
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Figure II.3B: Pax-5a and Pax-5d have opposite effect on transcription:
Pax-5a activates transcription of the reporter gene. The y42(3i)AS-CAT
reporter construct (0.5 pg) was transiently co-transfected with various
concentrations o f the pcDNA5a effector construct into NIH 3T3 cell line.
In each experiment, a pcDNA3 vector without insert was used as a negative
control and added to maintain equal amounts of transfected DNA in each
sample. The concentrations of the pcDNA5a construct (in pg) are
designated at bottom of the chart. Error bars show the mean ± S.E. (77= 5 ).
Percent CAT conversion was determined as described in “Materials and
M ethods” and normalized to the maximum percent conversion value within
each experiment.
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Figure II.3C and II.3D: Correlation between the amount of
transfected DNA and expression of Pax-5 proteins. Nuclear extracts
from COS-1 and NIH 3T3 transfected samples were analyzed by W estern
blot using the paired domain-specific antibody ED -1. The blot were
simultaneously probed with anti-TFIID serum to monitor the total amount
of loaded protein. Positions of Pax-5 isoforms are indicated. (C) The
increasing amounts o f Pax-5d expression construct (indicated above the
lanes) were transiently transfected into a non-lymphoid cell line, COS-1.
The nature o f the species detected at 35.4 kD is unknown, but may be
related to Pax-5x protein discussed later in text. (D) NIH 3T3 cell line was
transiently transfected with different amounts of either Pax-5a or Pax-5d
expression construct (indicated above the lanes).
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In earlier EMSA studies, we were able to show that in vitro translated forms of
Pax-5a and 5d have a similar affinity for Pax-5 DNA binding sites on the blk promoter
(Zwollo et al., 1997).

Based on the inhibitory effect of Pax-5d on promoter activity

(Figure II.3A), we next sought to investigate whether Pax-5d competes directly for
binding with Pax-5 a.

To test this, the reporter construct y42(3i)AS-CAT was transiently

co-transfected with various ratios of pcDNA5a and pcDNA5d into NIH 3T3 cells, as
shown in Figure II.3E.

This experiment showed that Pax-5d suppresses Pax-5a-

dependent activity o f the reporter. However, at least 20 times the amount of pcDNA5d
DNA was needed, as compared to pcDNA5a DNA, to detect significant decreases in Pax5a activity (Figure II.3E). This suggested either that Pax-5d protein was present at much
lower levels than Pax-5a, or that Pax-5a had a much higher affinity for Pax-5 binding
sites in this artificial promoter system, as compared to Pax-5 d. Interestingly, Western
blot analysis o f nuclear extracts from NIH 3T3 cells transfected with the same amounts of
either Pax-5a or Pax-5d expression constructs showed that the Pax-5d construct generates
less protein per pg DNA transfected as compared to Pax-5a (Figure II.3D). The exact
cause o f this phenomenon is unknown at this time; but such a discrepancy in the amount
o f produced protein may reflect the differences in either transcriptional/translational
efficiencies or protein stabilities o f the two Pax-5 isoforms. It is also possible that Pax-5d
needs a B cell specific factor that modulates its DNA binding affinity, which is absent in
NIH 3T3 cells.

Western blot analysis o f cytoplasmic extracts isolated from the

transfected samples revealed no Pax-5-specific bands, excluding the possibility that Pax5d protein is retained in the cytoplasm.
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Figure II.3E: Pax-5a and Pax-5d compete for DNA binding.
The y42(3i)AS-CAT reporter construct was transiently co-transfected
into NIH 3T3 cells with the pcDNA5a and pcDNA5d effector
constructs mixed in various ratios. In each experiment, a pcDNA3
vector without insert was used as a negative control and added to
maintain equal amounts o f transfected DNA in each sample. The Pax5a/Pax-5d ratios are indicated at the bottom o f the chart. Error bars
indicate the mean ± S.E. with the number o f replicates (n) indicated
below each bar.
Percent CAT conversion was determined as
described in “Materials and M ethods” and normalized to the
maximum percent conversion value within each experiment.
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In summary, our functional assays demonstrate that Pax-5d can suppress activity
o f an artificial promoter containing Pax-5 binding sites, and this effect is opposite to the
observed Pax-5a activation on the same promoter. In addition, we show that, when Pax5d is co-expressed with Pax-5a, it can suppress activity of Pax-5a in a dose-dependent
manner. Thus, the ratio o f Pax-5a to Pax-5d in the nucleus may provide a mechanism for
regulation o f expression o f Pax-5 target genes.

LPS-activation of mature B cells affects the ratio of Pax-5 proteins.
Our transfection studies suggested that the Pax-5a/Pax-5d ratio may regulate Pax5a function.

This was investigated by activating mature B cells with bacterial

lipopolysaccharide (LPS) and measuring Pax-5a and 5d levels before and after activation.
Nuclear extracts and total cellular RNA were prepared from samples collected before and
at various times after LPS treatment and analyzed using Western blot analyses and
RNAse protection assays.
First, we determined if LPS activation induced a shift in transcript levels of
isoforms Pax-5a and Pax-5d. The antisense Pax-5 riboprobe 10.1 (Zwollo et al., 1997)
was used to detect isoform Pax-5a as well as the novel sequence o f isoform Pax-5d.
Probe design and expected protected RNA fragments are indicated in Figure II.4A.
Riboprobe 10.1 detects exons 4 (partial) and 5 plus the novel sequence (nucleotides 447735) o f Pax-5d, resulting in a 288-nucleotide protected Pax-5d specific fragment. The
probe detects Pax-5a transcripts as a 160-nucleotide fragment corresponding to part of
exon 4 and exon 5 in the absence o f the novel sequence (Figure II.4A). A control tubulin
(pp) riboprobe was used for monitoring overall levels and quality o f RNA.
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pBS-10.1

I--------------------------- 1------^ ----- 1--------------1------------- [
exon 4
exon 5
novel
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104 (T3)
riboprobe 10.1-------- |----------------------------------- 1-------— |

Expected
bands:

-----------------------------------

392 nts

288 nts (5d or 5e)

160 nts (5 a or 5b)

Figure II.4A: Overview of the plasmid template pBS-10.1 (Pax-5d),
riboprobe 10.1, and expected protected regions on Pax-5a and Pax-5d
mRNA, as used in the RNAse protection assay. See “Materials and
M ethods” for details. The position o f the novel sequence unique to Pax5d and Pax-5e (nts 607-735) is indicated.
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Figure II.4B: RNAse protection assay on total RNA from small resting and
LPS-activated B lymphocytes. Small resting B cells (SRBs) were activated
with bacterial lipopolysaccharide (LPS) for specified periods of time, as
indicated, and analyzed for levels of Pax-5 a and Pax-5d RNA using the 10.1
probe (see Figure II.4A). The 288 nt band corresponds to Pax-5 transcripts
which contain sequence from exon 5 as well as the novel sequence, i.e. Pax-5d.
The 160 nt band corresponds to the Pax-5a transcripts which share exon 5 but
not the novel sequence. Sizes of protected fragments are indicated on the left
(nts). t, tRNA used as a negative control. The internal control RNA probe
ppTOO detects a 94 nt |3-tubulin transcript.
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SRBs were activated with LPS and samples were collected at day 0, 1, 2, 4
(Figure II.4B), 7, 8 , and 9 after stimulation (results not shown). From RNAse protection
assay data, it appears that there was no significant increase in the overall levels of Pax-5a
and Pax-5d transcripts.

Interestingly, the ratio of the 288 (Pax-5a) to 160 (Pax-5d)

protected bands remained unchanged for the entire nine days after LPS activation, and
this ratio was comparable to that in resting B cells (Figure II.4B, lane 2). In addition, no
new bands were seen in activated samples. This indicated that mitogenic stimulation of
B cells by LPS did not induce changes at the level o f alternative Pax-5 splicing.
Next, we determined whether activation of B cells by LPS changes the protein
levels o f Pax-5a and Pax-5d in the nucleus.

Western blot analyses of nuclear and

cytoplasmic extracts were performed using anti-Pax-5 antibodies ED-1 or 6G11.

The

polyclonal antiserum ED-1 is specific for the paired domain and detects all four Pax-5
isoforms (Table I).

6G11 is a monoclonal antibody that recognizes a C-terminal

sequence unique to Pax-5d (Table I; Anspach et al., submitted).

We used in vitro

translated Pax-5 a and Pax-5 d as controls and monitored total nuclear protein levels by
probing the filters simultaneously with an antibody that detects the basal transcription
factor TFIID. As expected, no Pax-5 bands were detected in cytoplasmic fractions from
either resting or activated B lymphocytes.
Results from Western blot analyses showed that nuclear Pax-5a protein levels
increased as B cells proliferated in response to LPS activation, peaking at day three and
four after stimulation, as shown in Figure II.5A. After day four, Pax-5a levels decreased
and by day six had returned to levels similar to those of resting B cells (day 0).
Interestingly, nuclear extracts from SRBs appeared to contain two bands in Pax-5a
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position, which we named 5a. 1 and 5a.2. The estimated size difference o f these bands is
~ 2.5 kD, which corresponds to approximately 20 amino acids. In contrast, only the Pax5a. 1 band was present in late activated B cells. This observation was confirmed when
samples were subjected to extended SDS-PAGE separation in the presence of high levels
(4%) o f SDS (Figure II.5B).

Further comparison of Pax-5 protein patterns between

resting and activated B cell samples revealed that resting B cell nuclear extracts displayed
an extensive banding pattern o f lower molecular weight species (<50 kD), as shown in
Figure II.5A (Lane 3).

This is likely the result of protein degradation, as it does not

correlate with the patterns o f existing splice variants o f Pax-5.

The number of

degradation bands decreased with time in activated samples. By day two, the fragments
were almost undetectable (Figure II.5A).

The observed change in banding pattern

indicates that Pax-5a protein may become stabilized upon LPS activation. It should be
noted that levels o f TFIID were undetectably low in the late-activation samples (day 6 day 8 ). The underlying cause and significance o f this phenomenon are unclear.
Using

the

anti-Pax-5d

antibody

6G11

(Figure

II.5C,

lower panel),

we

unexpectedly discovered that levels of the full-length Pax-5d protein were undetectable in
activated B cells.

Instead, the novel sequence-specific 6G11 detected a new, yet

unidentified band at 27 kD. The new species, which we termed Pax-5X, occurred at very
low levels in nuclear extracts from resting B cells (day 0) and during the first 2 days (48
hrs) o f LPS treatment (Figure II.5C, Lane 2-4). However, starting at day four after LPS
stimulation, we observed a dramatic increase in the intensity of the Pax-5Xband (Figure
II.5C, Lane 4-6).

The nature o f the Pax-5X species is unknown at this time.

represent either an N-terminal degradation product of Pax-5d or isoform Pax-5e

It may
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Figure II.5: Detection of Pax-5 proteins in resting and LPS-activated B cells
using the anti-paired domain serum ED-1. Nuclear extracts from SRBs and LPSactivated B lymphocytes were analyzed by Western blot using the anti-paird domain
serum ED-1. Days of LPS treatment are indicated. (A) Nuclear extracts from resting
(Day 0) B cells are characterized by extensive degradation. Pax-5 protein is stabilized in
activated samples where 5a. 1 is a predominant species. (B) Distinct 5a. 1 and 5a.2 bands
are clearly visible in a sample from partially activated B cells (Day 1) after an extended
electrophoresis in 4% SDS (see text). Anti-TFIID antibody was used to monitor the
amount o f total protein in the samples. The positions of Pax-5a.l, Pax-5a.2, Pax-5d and
TFIID are indicated on the left. Molecular weight markers in kilodaltons are indicated
on the right, ivt, in vtro translated protein.
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(although the band runs much higher in the gel then would be expected for the 19 kD
Pax-5e protein). This is not a degradation product of Pax-5a, as it contains the novel
sequence unique to Pax-5d and 5e.
We were unable to use the ED-1 antiserum to determine relative amounts o f Pax 5a, Pax-5d and Pax-5Xproteins, due to the presence of three strong bands in the region
around 35-25 kD in nuclear extracts from resting B cells (Figure II.5A), which made it
impossible to differentiate between Pax-5a degradation products and other Pax-5
proteins. Furthermore, ED-1 did not recognize the Pax-5Xband efficiently, unless greater
amounts o f total nuclear protein were loaded on the gel (not shown). This might be an
indication o f an incomplete paired domain, such as the one present in Pax-5e isoform.
In summary, LPS induced a dramatic upregulation of Pax-5X protein levels
concomitant with a corresponding drop in Pax-5a.2 levels. This resulted in a 15.6 (+/3.6) fold decrease in the ratio o f Pax-5a to Pax-5X protein after resting B cells were
activated with LPS (Figure II.5D). It should be noted that the ratio o f Pax-5a to Pax-5X
was calculated based on the relative intensities of the corresponding bands (“see
“Materials and M ethods”), and does not refer to the molar ratios o f the two proteins in
samples.

The molar ratios could not be estimated because Pax-5a and Pax-5X protein

species were detected using two different antibodies with unknown affinities, which
made it impossible to determine the precise stoichiometry o f antibody binding.

Presence of specific Pax-5 protein species in B cell lines.
Our observation that LPS induced a shift in the Pax-5a/ Pax-5Xratio in primary B
lymphocytes led us to further examine this phenomenon in B cell lines representing
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specific antibody 6G11 are shown on the bottom panel. Positions of different Pax-5 species are
indicated. Pro-B, pro-B cell stage; Imm, immature B cell stage; Mat, mature B cell stage; Act, pre
secretor/activated B cell stage; PC, plasma cell stage.
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various stages o f late B cell differentiation. Previous studies had already shown that the
transcript levels o f Pax-5a and Pax-5d remain unchanged during B cell development until
both isoforms cease to be expressed in plasma cells (Zwollo et al., 1997). Relative levels
o f Pax-5a.l, Pax-5a.2, Pax-5d, and Pax-5Xproteins were determined in nuclear extracts
from pro-B, immature B, mature B, pre-secretor B, and plasma cell lines using ED-1 and
6G 11 antibodies (Figure II.6 A).
Using Western blot analysis, we observed that the nuclear levels o f Pax-5a
isoform do not change significantly in different B cell lines (Figure II.6 A, E D -1/TFIID
panel). In addition, the degradation pattern seen in resting B cells was absent from most
B cell lines (except the mature B cell line 2PK3).

In contrast to Pax-5a isoform, the

nuclear levels o f Pax-5Xspecies were undetectable at the pro-B stage, but later increased
in a stage-dependent manner (Figure II.6 A, panel 6G 11). Isoform Pax-5d was present at
very low levels in pro-B cell lines (Figure II.6 A, panel 6G11, lanes 1,2), and was
undetectable during late stages of B cell development (Figure II.6 A, 6G 11 panel, lanes 911). Interestingly, as in SRBs, Pax-5d and Pax-5x are expressed at the comparable levels
in the immature and early mature B cell lines (WEHI-231 and B17.10, respectively).
However, two highly differentiated B cell lines en route to the plasma cell stage (2PK3
and C H I2) possess the Pax-5X, but not Pax-5d species, similar to the pattern in LPSactivated normal B cells.

The plasma cell line Sp2/0, as expected, had no detectable

levels o f any Pax-5 proteins.
The relative intensity o f the bands was quantified (see Methods), and the ratio of
nuclear Pax-5a to Pax-5Xwas determined (Figure II.6 B). As in the previous experiments,
the estimated values reflect not the molar ratios o f the two proteins, but the relative
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intensity o f the corresponding bands. A significant decrease in the Pax-5a to Pax-5Xratio
correlates with differentiation state o f the cell lines, and this is in agreement with our
LPS-activation experiments using normal B cells. The results suggest that specific Pax5Xprotein species play an important regulatory role during B cell differentiation.

Changes in Pax-5a DNA binding after LPS activation.
Activities o f transcription factors can be regulated by a variety of mechanisms.
One common post-translational means of regulation is alteration o f a factor’s DNAbinding activity through structural modifications of its DNA-binding domain (Steegenga
et al., 1996; Tell et al., 1998). Hence, our next goal was to determine whether LPSactivation o f mature B cells results in a change in DNA-binding activity o f Pax-5
proteins, using EMSA.

Previous EMSA experiments using SRB nuclear extracts had

identified the presence o f two distinct, Pax-5a-like complexes, which were named 5a. 1
and 5a.2 (Anspach et al., submitted).
Comparison o f nuclear extracts from resting and LPS-activated B cells showed a
shift in the relative amount o f the 5a. 1 and 5a.2 complexes (Figure II.7A). In nuclear
extracts from SRBs, the faster migrating species (5a.2) was a predominant band.
Interestingly, after LPS treatment, the relative intensity o f the two bands reversed,
shifting toward the slower migrating species (5a. 1) until 5a. 1 became the predominant
band in the late-activation samples (Figure II.7A, lanes 8-10).

The EMSA results

confirmed our earlier observation that Pax-5 a protein is more susceptible to degradation
in SRBs, as compared to late stage LPS-activated samples. Several molecular species (all
lower than Pax-5a) were present in nuclear extracts from SRBs and from early activated
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samples (Figure II.7A, Days 0-4, lanes 3-7), but absent from the late activation stage
(Figure II.7A, Days 7-9).
Next, nuclear extracts from resting and LPS-activated B cells were pre-incubated
with one o f the following antibodies: ED-1, OC-1, Pax-5/N19, or Pax-5/C-20 (for
specificities, see Table I), followed by incubation in the presence o f the probe. Earlier
studies have shown that all Pax-5 species that are capable of DNA-binding can interact
with the paired domain-specific antibody ED-1 (Zwollo et al., 1998).

Our data

demonstrated that these species also interact with Pax-5/N-19 antibody (Figure II.7B,
Lane 6 ). This indicated that all the DNA-protein complexes detected in SRB samples
shared not only the paired domain sequence, but also the N-terminal 19 amino acids
which are detected by the Pax-5/N-19 antiserum.
specific Pax-5/C-20 antiserum

In contrast, neither the C-terminus-

(Figure II.7B, Lanes

5,

8,

10) nor the partial

homeodomain-speciflc OC-1 antiserum (result not shown) was effective in inhibiting
formation o f the lower molecular weight DNA-protein complexes.

Together, these

results suggest that all the lower molecular weight Pax-5-DNA complexes contain the Cterminally truncated Pax-5 proteins that possess the paired domain sequence and share an
intact N-terminal region.
The Pax-5/C-20 antibody recognizes the 22 most C-terminal amino acids of Pax5a.

In supershift EMSAs, C-20 recognized and supershifted the 5a. 1 band, which

represents the most abundant Pax-5a species in activated cells (Figure II.7B, Lanes 8 , 10,
12, 14). Significantly, Pax-5/C-20 was unable to supershift the slightly lower migrating
5a.2 band present in resting and early activated cells (Figure II.7B, lanes 5, 8 , 10, 12).
Together with the results o f ED-1 and Pax-5/N-19 supershift EMSAs, this observation
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suggests that 5a. 1 and 5a.2 proteins differ in structure at the C-terminus, but not the Nterminus. This is particularly interesting given the presence of a repressor domain within
the last 33 amino acids o f Pax-5a (Dorfler and Busslinger, 1996).

W hether the C-

terminus o f 5a.2 is modified, thereby masking the epitope recognized by C-20, or
whether it is absent altogether, could not be determined using this method. However, the
results o f Wetern blot analysis (Figure II.5A,B) suggested that 5a.2 may have lost the Cterminal region o f about 20 amino acids. If the Pax-5a C-terminus is indeed absent, this
could be either the result of specific proteolysis, or alternatively, the result of alternative
RNA splicing. In conclusion, the presence o f the C-terminal repressor sequence on Pax5a. 1 appears to correlate with B cell activation.
To test the possibility that the 5a.2 protein species represents a novel, alternatively
spliced Pax-5 variant, we performed RNase protection assays using an anti-sense
riboprobe pBS.1.2 (Zwollo and Desiderio, 1994) that covers a region between exons 8
and 10 o f Pax-5a. Using RNA prepared from SRBs and LPS-activated B cells, we found
no evidence for the existence o f alternatively spliced isoforms that were missing either
exon 8, 9, or 10 (data not shown).

This is in agreement with earlier experiments,

including the screening o f a spleen cDNA library, which also showed no evidence for
expression o f isoforms lacking the C-terminal repressor domain coding region (Zwollo et
a l., 1997).
Lastly, the EMSA approach could not be used to assess levels o f Pax-5d- and
Pax-5x-containing complexes. We were unable to specifically identify Pax-5d protein in
SRBs, due to Pax-5a degradation products running with similar mobility to Pax-5d on
denaturing gels.

This problem could not be resolved due to the unavailability of a
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suitable antibody. The anti-Pax-5d monoclonal 6G 11 does not recognize the native form
o f Pax-5d efficiently (Anspach et al., submitted) and, hence, could not be used for
EMSAs. Analysis o f LPS-activated samples by EMSA detected neither Pax-5d- nor Pax5x-specific complexes.

The absence o f Pax-5d bands is not surprising since Pax-5d

protein was not detected in the activated samples (as determined by Western blot). The
lack o f DNA-binding activity in Pax-5X species is probably due to its incomplete paired
domain, in agreement with the hypothesis that Pax-5Xrepresents Pax-5e.
In summary, EMSA analysis revealed that LPS-activation of normal mature B
cells induced post-translational changes o f isoform Pax-5a. This resulted in a significant
decrease in levels o f a Pax-5a species (5a.2) in which the C-terminal repressor domain
has been either lost or modified.

Simultaneously, LPS activation correlated with an

increase in Pax-5a species with an intact repressor domain, namely Pax-5a. 1.

Post-

translational changes o f the repressor domain of Pax-5a may modulate its function in
LPS-stimulated B lymphocytes.

D ISC U SSIO N
In this study we analyzed the function of Pax-5d in relation to Pax-5a activity.
Among the Pax-5 isoforms generated by alternative splicing, Pax-5a and Pax-5d present a
special interest because they are the two most abundant isoforms in mature B cells, are
both capable o f binding to DNA, and are dramatically different in the composition of
their C-termini. Studies on the related Pax-8 gene had shown previously that it expresses
at least six alternative isoforms that are developmentally expressed and display
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differential tranactivating potential (Kozmik et al., 1993). Similarly, Pax-5 isoforms may
differ in transactivating potential as well.
Our results demonstrated that, opposite to Pax-5 a, Pax-5 d functions as a repressor
o f transcription. The two isoforms compete for binding to Pax-5-specific sites on DNA,
Contrary to our initial hypothesis, the ratio of Pax-5a to Pax-5d does not seem to change
significantly during B cell differentiation due to very low protein levels o f Pax-5d in
normal B lymphocytes, as well as in different B cell lines. However, the ratio o f Pax-5a
to Pax-5e, the novel, Pax-5e-like species, decreases dramatically during late stages o f B
cell differentiation, suggesting an important role for the Pax-5X protein in regulation of
transcription during B cell activation.

In addition, we showed that activation signals

induce stabilization o f Pax-5a isoform leading to the retention o f the C-terminal repressor
sequence.

Together, our data indicates that, in activated B lymphocytes, the

transcriptional activity o f Pax-5a (BSAP) transcription factor may be regulated through
translational and post-translational mechanisms.

The pathways involved in these

mechanisms are directed to inhibition o f Pax-5a activity, which is achieved either through
structural modifications Pax-5 a protein or by upregulation of the alternative Pax-5
isoform(s) with dominant-negative functions.

Pax-5d is a repressor of Pax-5a activity.
In the first set o f results, we demonstrate that Pax-5d has a transactivation
function opposite to that o f Pax-5a and acts as a transcriptional suppressor. In addition to
repressing the activity o f endogenous Pax-8 in the kidney cell line COS-1 in a dosedependent manner, more significantly, we also show that Pax-5d can similarly repress
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activity o f Pax-5a in NIH 3T3 cells. Thus Pax-5a and Pax-5d have an opposite regulatory
function in vivo.

Together, our functional studies suggest that Pax-5d functions as a

transcriptional repressor that regulates activity of Pax-5a and affects expression o f Pax-5
target genes.
The observed repressor function o f Pax-5d is most likely the result o f the absence
o f a transactivating domain, although this needs further investigation. The lack o f both
the transactivating domain and the adjacent, extreme C-terminal repressor domain, which
are present on Pax-5a, prevents interaction of Pax-5d with the basal initiation complex.
While different at the C-terminal regions, the two isoforms share an intact paired domain
and the octamer sequence. The latter has been shown to interact with the co-repressor
Groucho4 although it is unclear what the functional significance o f this interaction is in
the B cell (Eberhard et al., 2000). Both the octamer m otif and the partial domain are
capable o f interacting with the Retinoblastoma protein and the TATA-box binding
protein (Eberhard and Busslinger, 1999), but it remains to be determined whether Pax-5d
would interact with such proteins as well, as the Pax-5 a specific partial homeodomain
may also be necessary for this interaction (Eberhard and Busslinger, 1999). The presence
o f two protein-protein interaction regions, identical to those found in Pax-5a isoform,
may allow Pax-5d bind to the partner-proteins that can be involved in interactions with
Pax-5a. The shared specificity for binding partners may result in a competition between
Pax-5a and Pax-5d for binding not only to Pax-5 recognition sites on DNA, but also for
certain accessory factors and partner-proteins.
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The ratio of Pax-5 proteins changes as mature B cells become activated.
Our data clearly show that regulation o f Pax-5a and Pax-5d activity during B cell
activation by LPS treatment does not occur at the transcriptional level. The ratio o f Pax 5a/Pax-5d mRNA remains unchanged during the entire activation period o f 9 days. In
contrast, a number o f changes were observed at the protein level. An initial increase in
Pax-5a levels in nuclear extracts was observed at days 2-4 after LPS stimulation
corresponding with active B cell proliferation, followed by a decrease to pre-LPS levels
by day 5 or 6, as reported previously by Wakasuki et al. (1994).

Contrary to our

hypothesis about the role of the Pax-5a/Pax-5d ratio in regulation of Pax-5a function, the
nuclear levels o f Pax-5d were very low in resting B lymphocytes and undetectable in
activated cells.

However, we detected a new band at ~27 kD which represents a yet

unidentified protein species named Pax-5X.
dramatically

in nuclear extracts

during

The intensity o f Pax-5X band increases
the

late

activation

stages

(days

5-9),

concomitantly with the decrease in the Pax-5a levels. Together, these changes lead to a
significant decrease in the 5a/5x ratio as B cells become activated by LPS. The Pax-5X
band has also been detected in nuclear extracts of various B cell lines, where its intensity
was higher in cell lines representing late stages of differentiation. Thus, the ratio of Pax5a to Pax-5Xproteins decreases during activation and differentiation of B lymphocytes.
The exact nature o f Pax-5X species is unknown at this time.

Western blot of

resting and activated SRBs shows that the 27 kD band can interact with the novel
sequence-specific antibody 6G11, but is undetectable using the paired domain antiserum
ED-1. These results indicate the presence of the novel sequence and suggest that the
paired domain is either incomplete or absent. The fact that Pax-5X does not possess any
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detectable DNA-binding activity suggests that the Pax-5Xband may represent the Pax-5e
isoform. However, the expected size of Pax-5e is 19 kD. One possible explanation for
the ~8 kD difference in size between Pax-5e and Pax-5X is that the band represents a
modified form o f the Pax-5e protein.

Pax-5e might be modified through such post-

translational modifications as O-glycosylation or formation o f disulfide bonds. These,
however, requires further investigation. Finally, we cannot exclude the possibility that
Pax-5X band represents an N-terminal degradation product o f Pax-5d. Identification of
Pax-5Xspecies is the focus o f our current research.

B cell activation corresponds with an increase in Pax-5a.l protein.
The protein patterns o f Pax-5a changed during the early stages o f activation (days
1-4), and this correlated with activation-induced proliferation o f B cells (Wakatsuki et al.,
1994). Most strikingly, activation signals triggered an increase in the relative level of
5a. 1 and concomitant decrease in 5a.2 molecular species. In our experiments, we have
shown that the emergence o f a slower migrating 5a. 1 complex was due to a modification
at the C-terminus o f Pax-5a protein.
We hypothesize that specific proteases remove the C terminal sequence from Pax5a. 1 in resting, but not activated/proliferating B cells. Proteases also apparently cause
multiple degradation bands in resting B cell nuclear extracts.

The observed effect is

unlikely to be a result o f nuclear extract preparation, because all the buffers used for this
procedure

contained several protease inhibitors

(see “Materials and M ethods’').

Moreover, the identical patterns were observed in several independent experiments in
which samples originating from different sources were used (i.e. cell lines, different

strains o f mice). It is unclear how Pax-5a in activated B cells and proliferating cell lines
is “protected” from specific proteolysis. To confirm this hypothesis, the half-life of Pax 5a protein has to be determined in resting and LPS-activated B cells, which can be
achieved using pulse-chase assays.
In support o f a functional role for C-terminus-initiated degradation, is the
presence o f a potent repressor domain in this region (see Figure II. 1; Doefler and
Busslinger, 1996). Since both 5a. 1 and 5a.2 forms are present in resting B cells, but only
the repressor-containing form is present in proliferating B cells, this may define the set of
Pax-5 target genes during each of the two developmental stages.

Nutt et al. (1998)

showed that a subset o f Pax-5 target genes, including those for which Pax-5 functions as
a recruiter (e.g. mb-1), can be regulated by the paired domain alone. In contrast, other
target

genes

require

the

complete

transactivating domain (e.g. CD19).

Pax-5a

sequence

including

the

C-terminal

We speculate that, in resting B cells, specific C-

terminal proteolysis generates an array of shorter Pax-5a with distinct transactivating
activities.
Proteolysis is a common mechanism that quickly and irreversibly regulates
transcription factor function. This means o f regulation is particularly useful when cells
need to respond rapidly to changes in their environment. Several eukaryotic transcription
factors, including NF- kB, p53, c-Myc, and c-Jun, have been shown to be regulated by
proteolytic events, most o f which involve the ubiquitin-proteasome pathway (reviewed
in Peters, 1994; Pahl and Baeuerle, 1996). Proteolytic degradation may occur either in
cytoplasm (e.g., N F- k B (Thanos and Maniatis, 1995)) or in the nucleus (e.g., H IF -la
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(Salceda and Caro, 1997)), indicating that this process is mediated by the specifically
localized proteasome systems.
The lability of many regulatory proteins is critically important under normal
conditions.

The disruption o f proper steady-state levels o f these proteins may have

deleterious consequences for a cell (Treier et al., 1994). However, in some cases, protein
stability changes drastically when cells are subjected to a stressful stimulus. Wild-type
p53, for instance, is a short-lived nuclear transcription factor which becomes stabilized
and activated following cellular stress or DNA damage (Pahl and Baeuerle, 1996). The
exact mechanism o f this stabilization is not clearly understood, but thought to be
regulated by multi-site phosphorylation (Steegenga et al., 1996; Meek, 1998). Another
example is the hypoxia-inducible facto r-la (H IF -la), a transcriptional activator complex
involved in regulation o f several hypoxia-regulated genes (Salceda and Caro, 1997).
Under normoxic conditions, H IF -la is continuously degraded in the nucleus by the
ubiquitin-dependent pathway. The lack o f oxygen, or hypoxia, induces stabilization and
accumulation o f H IF -la followed by subsequent activation o f its target genes (Salceda
and Caro, 1997). The signals triggering stabilization o f the H IF -la protein are currently
unknown; however, some evidence suggests that redox-mediated changes might be
involved (Salceda and Caro, 1997).
Thus, stress-induced stabilization o f transcription factors is a well-documented
phenomenon which may take place in activated B lymphocytes.

It remains to be

determined whether Pax-5a degradation, occuring in resting B cells, involves the
ubiquitin-proteasome pathway. Further investigations are needed to identify the factors
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which contribute to susceptibility of Pax-5a to degradation, as well as to its stabilization
during activation.

Effects of changes in Pax-5 proteins on Pax-5/BSAP target genes
The increased levels o f Pax-5Xinduced during B cell activation may inhibit Pax5a function through competition for various accessory factors, thereby aiding in downregulation o f certain Pax-5 target genes during this stage. One possible effect of such
competition is the relief o f Pax-5 a repressor function.

Many of the genes negatively

regulated by Pax-5a, such as J chain and Ig heavy chain genes, are not expressed until the
late stages o f B cell differentiation (pre-secretor to mature plasma cell). Their expression
indicates an inhibition o f negative transcriptional control exerted by Pax-5 a, although
Pax-5a is clearly still present in the nucleus during this time. Although the mechanism of
de-repression is currently unclear, it is possible that Pax-5x plays an important role in
attenuating Pax-5a activity during transition o f B cells to the plasma cell stage.
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Chapter III
Preliminary Studies of the Activity of Pax-5 isoforms in
vivo and in vitro

The studies presented in this chapter aimed to address various aspects o f Pax-5
function using alternative experimental approaches.

These included development o f a

novel transfection system for the analysis o f Pax-5a/Pax-5d competition (Section 1),
examination o f B cell activation in aged B lymphocytes (Section 2), and activation
studies in the immature B cell line WEHI-231 (Section 3). The experiment described in
Section 4 is a part o f an ongoing study that deals with identification of Pax-5Xspecies.

1. Staggered Transfections
In Pax-5d, the entire transactivation domain and the homeodomain homology
region have been replaced with a novel sequence o f unknown function (Zwollo et a l.,
1997).

As stated previously, the absence of an important C-terminal module may

significantly change the activation function Pax-5 (Anspach et al., submitted).

Thus,

while the Pax-5d isoform can efficiently bind to DNA, it fails to interact with the
transcription initiation complex and can have a dominant-negative effect on transcription.
This hypothesis is supported by transient transfections studies presented here, which
revealed that Pax-5d and Pax-5a isoforms have the opposite effects on the transcription of
an artificial minimal promoter construct containing Pax-5 binding sites from the CD 19
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promoter (Chapter II). Functional studies also indicated that the two isoforms (Pax-5a
and Pax-5d) may compete for binding to Pax-5 DNA binding sites (Chapter II).
Intriguingly, in our competition experiments, the activity o f Pax-5a was inhibited only
when very high levels o f Pax-5d expression construct were trasnsfected, and the Pax5a/Pax-5d ratio (based on the amount o f the transfected DNA) was less than 1/10. Three
possibilities could explain these findings. First, Pax-5d protein may be degraded more
rapidly than Pax-5a (at least in the chosen cell line).

Second, Pax-5d may have a lower

affinity for Pax-5 binding sites in vivo, as compared to Pax-5a. As a result, Pax-5d may
be unable to bind to DNA in the presence of Pax-5a. Finally, it cannot be excluded that
the two isoforms differ in the rate and efficiency of transcription and/or translation.
To rule out the possibility of differential affinity, a “staggered” transient
transfection system was developed. In this system, the reporter construct y42(3i)AS-CAT
was first co-transfected with the Pax-5d expression construct followed, 20-24 hr later, by
a second transfection on the same cells with the Pax-5a expression construct alone. Cells
were incubated for additional 20-24 hr and then processed as cell lysates (for CAT
assays) and nuclear extracts (for Western blot analyses and EMSA) according to standard
methods (Chapter II). A control co-transfection with HBIICAT and pcDNAS (Chapter
II) was performed to determine the effect of “staggered” transfections on transfection
efficiency. Additional controls included a panel of samples transfected at either first or
second day only. These controls were designed to assess the levels o f protein expression
at 24 and 48 hr after introduction of the constructs (Figure III. 1A).
The rationale behind this approach was based on the assumption that if the
pcDNA5d effector construct was introduced into the system prior to Pax-5a expression,
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Figure III.1A: “Staggered” transfection method. Various combinations of
constructs were transiently co-transfected into NIH 3T3 cell line in a “staggered”
fashion: the reporter construct y42(3i)AS-CAT was first co-transfected with the
Pax-5d (or Pax-5a) expression construct followed, 20-24 hr later, by a second
transfection on the same cells with the Pax-5 a (or Pax-5 d) expression construct
alone. A pcDNA3 vector without insert was used to maintain equal amounts of
transfected DNA. After total 48 hr of incubation, the samples were collected, and
cell extracts were analyzed by CAT assay, Western blot, and EMSA.
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the Pax-5d isoform may have a chance to occupy the binding sites and, later, prevent
Pax-5a from binding.

It was, therefore, hypothesized that binding competition could

occur at low Pax-5d concentrations if this transcription factor had a sufficient time to be
synthesized and to bind to a target site on DNA without competition from Pax-5a.
CAT assay results from the pilot experiments provided some evidence for that
hypothesis (Figure III.IB, see “Samples”).

With the Pax-5a/Pax-5d ratio o f 1/5

(according to the amount o f transfected DNA), we observed a three fold decrease in the
relative CAT conversion for samples transfected with the Pax-5d effector construct first
followed by the Pax-5 a construct transfection on the second day, as compared to the
sample with the reversed order of the introduced constructs (compare 55.6% for [5a+5d]
to 18% for [5d+5a]).

However, a more careful experimental design, which included

additional controls, proved our initial results unreliable due to significant differences in
the protein levels present in the samples after 24 and 48 hours of transfection (Figure
III.IB , see “Controls”). For example, the CAT expression level in the Pax-5a control
samples collected 48hr post-transfection was 10.6 fold higher than in those samples
which were incubated only for 24hr (81.7% for [5a-day 1] vs. 7.7% for [5a-day 2]).
Likewise, the length o f incubation had an effect on the CAT activity induced by the
HBIICAT construct (compare 100% for [HBIICAT-day 1] to 79.4% for [HBIICAT-day
2]) and in the samples co-transfected with Pax-5a and Pax-5d simultaneously (compare
28.5% for [5a/5d-day 1] to 7.2% for [5a/5d-day 2]). After a thorough analysis of these
data, we concluded that the difference in CAT activity observed in the “staggered”
samples is not based on Pax-5a/Pax-5d binding competition, but is more likely to be
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Controls- Day 1

j

Controls- Day 2

;

Samples

Figure III.1B: CAT assay of staggered transfection samples. The effector
constructs, pcDNA5a (0.1 jag) and pcDNA5d (0.5pg), were cotransfected into
NIH 3T3 cell line in combination with the y42(3i)AS-CAT reporter construct
(0.5jag). The effectors were introduced in a staggered fashion to assimilate a
situation in which Pax-5d binds to DNA without competition from Pax-5a (see
text for details). Controls included samples transfected with one or both
constructs at either day 1 or day 2 of the experiment. Percent CAT conversion
was determined as described in “Materials and M ethods” (Chapter II) and
normalized to the percent conversion value for “HBIICAT- d a y l” sample set at
100%.
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determined by different concentrations o f Pax-5a present in the samples at any particular
time-point.
To confirm conclusions that were made based on the experimental data, nuclear
extracts from the transfected samples were analyzed using Western blot and EMSA as
described (see “Materials and Methods”, Chapter II). Pax-5a and Pax-5d protein levels
were assessed and DNA-binding patterns determined using isoform-specific antibodies
(ED-1 and 6G11) (Figure III.ID ) and the CD19/BSAP probe (Figure III. 1C). The results
o f these experiments do indeed indicate that, after 24 hr post-transfection, the protein
levels o f both isoforms are barely detectable (Figure III.ID ), which consequently results
in a low signal from the bound probe in EMSA (Figure III. 1C). In contrast, after 48 hr
incubation, the protein levels are readily detectable allowing for more accurate data
analysis.
Although Western blot analyses and EMSA were used for an assessment o f the
protein levels in the transfected samples, it is important to note that the levels o f Pax-5a
and Pax-5d in the nuclear extracts are not necessarily equivalent to those that drive the
expression o f the CAT gene measured by CAT assay (Figure III. IE). The measurements
o f Pax-5a and Pax-5d levels obtained by Western blot for each time-point correspond
with CAT activity at some undetermined time in the future, after transcription and
translation o f CAT protein (“delay factor”). Thus, the main complication with using the
“staggered” transfection approach is that it is difficult to correlate the levels o f Pax-5
isoforms at a given time-point with the activity of the target promoter at that time. This
problem can be solved by determining the currently unknown “delay factor” . This will
involve: 1) measuring protein levels of Pax-5a and Pax-5d at several points within the
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Figure III.l (see next page): Analyses of expression levels and DNA-binding
activities of Pax-5a and Pax-5d proteins in “staggered” transfection samples.
NIH 3T3 cell line was transfected with Pax-5a and Pax-5d expression constructs
using the “staggered” transfection approach (see text). Control samples were used
to determine the relative levels o f the expressed proteins after 24 (day 1) and 48
(day 2) hr post-transfection. (C) Nuclear extracts (1 pg) from the “staggered”
transfection samples were analyzed by EMSA using CD19/BSAP probe (see
Chapter II, “Materials and Methods”), ivt, in vitro translated Pax-5a (1 pi lysate)
and Pax-5d (2 pi lysate). (D) Nuclear extracts from the “staggered” transfection
samples were analyzed by Western blot using the paired-domain-specific
antibody ED-1. The blot was simultaneously probed with anti-TFIID antibody to
monitor the amount o f total protein in the samples. The positions o f Pax-5a
proteins and TFIID are indicated by arrows. The band at ~27 kD represents Pax5Xspecies (for more detail, see Chapter II and Section 4).
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staggered transfection time-period to establish the patterns and dynamics o f their
expression; 2) measuring CAT activity over a time range in the samples transfected with
each individual isoform, as well as their combinations; and, finally, 3) determining how
long does it take from binding of Pax-5 transcription factors to the promoter of the
y42(3i)AS-CAT DNA construct, to expression of CAT protein. In these investigations,
assaying the system for CAT transcripts using RNAse protection assay may provide
additional information about the dynamics o f CAT transcription/translation.
In conclusion, the “staggered’" transfection approach did not provide unequivocal
data that would help to resolve the problem of concentration disparity in Pax-5a/Pax-5d
binding competition.

It is still unclear what conditions and requirements have to be

satisfied in order for such competition to occur. Determination and comparison o f Pax-5a
and Pax-5d protein half-lives may help in better understanding o f the interactions
between the two isoforms. Based on the results of those experiments, it might possible to
predict

whether

Pax-5a/Pax-5d

binding

competition

is physiologically

relevant.

Although the “staggered” transfections did not provide conclusive results at this time, the
approach can be potentially developed into a useful tool for studies of protein-protein
interactions between Pax-5 isoforms and for investigation of their cooperative effect on
gene transcription.

98

Pax-5a
Pax-5d

Protein
Levels

CAT
Delay’
factor

pcD N A 5a
introduced

CA T expression
starts

Delay’
factor

pcDN A5d
introduced

Delay’
factor

Time

Sam ples collected
for nuclear extracts

Figure III.1E: Hypothetical diagram of expression patterns of Pax-5a, Pax5d, and CAT proteins in “staggered” transfection experiments.
When
pcDNA5a and y42(3i)AS-CAT constructs are co-transfected into NIH 3T3 cell
line, expression o f the CAT protein is delayed by an unknown factor which
reflects the time necessary for transcription/translation o f Pax-5a and its
interaction with the CAT promoter. Subsequent introduction of the pcDNA5d
construct will inhibit the expression of CAT, however this event will also be
delayed. Consequently, the transactivating effect exerted by a combination of
Pax-5 a and Pax-5d that is present in the system at any particular time-point (such
as indicated by a star) can only be assessed by measurements of CAT activity at
the later time-point. Therefore, the protein levels o f Pax-5a and Pax-5d
determined using Western blot and EMSA do not reflect the concentrations of
these proteins effective in the regulation o f the CAT promoter.
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2. LPS-activation o f SRBs isolated from aged mice
Aging has been associated with profound changes in the immune system
including elevated susceptibility to infections, increased incidence of autoimmune
disorders, and decrease in quality of humoral immune response (Ghia et al., 2000). Ageassociated decline o f humoral immunity results from altered B lymphopoesis, reduced
production o f B cells, and an impaired antibody response.

The immunoglobulins

generated by the aging immune system often possess autoreactive properties in addition
to their decreased diversity and low affinity (Song et al., 1997; Ghia et al., 2000). While
no experimental evidence is available at this time, it would not be surprising if the
dramatic changes in the characteristics of the B cell could be correlated with alterations in
the expression or activity o f transcription factors involved in development and
differentiation o f B lymphocytes. This has already been demonstrated for senescent T
lymphocytes which display age-related decline in the expression o f genes encoding such
products as c-Fos, c-Jun, c-Myc, and c-Myb (Pieri et al., 1992; Song et a l., 1992).
Alteration o f gene transcription occurring in aged cells inevitably involves changes in the
associated

regulatory

molecules.

Consequently,

age-related

deregulation

of

hematopoietic transcription factors may have a powerful impact on the functioning and
health o f the senescent immune system.
Recent investigations in our lab have focused on identification of age-related
changes in B cell-specific transcription factor Pax-5. Resting mature B cells o f young (24 month old) and aged (18-23 month old) mice were used for comparative analyses of
Pax-5a and Pax-5d isoforms, their expression patterns and DNA-binding activities
(Anspach et al., submitted).

It was found that, while the protein levels o f the two
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isoforms remain constant in both experimental groups, the DNA-binding activity o f Pax5a, but not Pax-5d, is significantly reduced in aged B cells. This decline in DNA-binding
has been shown to correspond to changes in the expression of at least two Pax-5 target
genes, both o f which are associated with Ig genes and negatively regulated by Pax-5
(Anspach et al., submitted). In that work, one of the proposed hypothesis stated that an
age-associated decrease in Pax-5a DNA-binding activity may result in deregulated class
switching and attenuated proliferative capacity of activated B lymphocytes. Thus, one of
the projects presented here aimed to analyze mitogenically stimulated B cells obtained
from aged mice, and investigate the effect of LPS treatment on the expression and DNAbinding patterns o f Pax-5 proteins.
Splenic small resting B lymphocytes were obtained from six 21 month old
BALB/c mice and cultured in LPS-containing medium as described (Chapter II). It is
important to note that, while in these experiments the isolated B cells were pooled for
convenience, this practice should be avoided in the future due to the potentially high
variability in biochemical and physiological characteristics among aged animals.

The

samples o f LPS-treated cells were collected at 0 (Day 0), 48 (Day 2), 96 (Day 4), 144
(Day 6), and 192 (Day 8) hours post-stimulation, and processed for nuclear extracts,
which were further used for Western blot analyses and EMSA.

Curiously, the

experimental cultures contained a high proportion of adherent lymphocytes which had
not been seen in the previous studies with SRBs from young mice. This phenomenon
could be a result o f the increased proportion o f cells expressing high levels of leukocyte
function-associated antigen-1 (LFA-1).

LFA-1 belongs to the integrin family of cell

surface molecules which have an important role in cell adhesion and are expressed at
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moderate levels on all subsets o f leukocytes (Hogg and Berlin, 1995). Typically, effector
and memory lymphocytes are characterized by elevated levels of LFA-1 expression
which amplifies their capacity for migration into inflamed tissues (Hogg and Berlin,
1995).

Age-associated changes in lymphocyte adhesion have been reported for the

senescent SAM-P/8 and SAM-R/1 mice, and are attributed to the increase in the relative
number o f memory cells expressing high levels of LFA-1 (Powers et al., 1992).
Western blot analysis o f LPS-activated aged samples revealed no significant
changes in either Pax-5a or Pax-5Xprotein levels (Figure IIF2A). This is in contrast to
activated young SRBs in which variable levels of the two protein species were observed
at different time-points o f LPS stimulation, with the Pax-5a/Pax-5x ratio decreasing
gradually in activated B lymphocytes (see Chapter II, Figure II.5A-D).

The Pax-5a.2

band was not clearly defined in resting aged B lymphocytes, although, similarly to young
SRBs, these samples showed an extensive Pax-5 degradation pattern which was absent
from the nuclear extracts o f activated lymphocytes (Figure III.2A, ED-1/TFIID panel).
In contrast to young SRBs, the Pax-5d band was not detectable at any time-point (Figure
III.2A, 6G11 panel).
Next, nuclear extracts from LPS-activated aged SRBs were analyzed by
electrophoretic mobility shift assay using a CD19/BSAP probe (Chapter II). Prior to the
assay, nuclear extracts were pre-incubated without the probe with Pax-5/C-20 antibody
(Table I) to distinguish between Pax-5a. 1 and Pax-5a.2 species identified in our earlier
studies (Anspach et a l., submitted; Chapter II). In agreement with data on young mice
(Anspach et a l., submitted), the nuclear extracts o f aged resting B cells also had no
detectable Pax-5a bands, indicating a dramatic decrease in the amount o f Pax-5a protein

102

TFIID

ED-1/TFIID

Figure III.2A: Western blot of LPS-activated SRBs from aged mice. Nuclear
extracts from LPS-activated aged (from 21 month old mice) B lymphocytes were
separated on SDS-PAGE, and filters were probed with anti-paired domain serum
ED-1 (top panel) and the novel sequence-specific antibody 6G 11 (bottom panel).
Anti-TFIID antibody was used simultaneously with E D -1 to monitor the total
amount o f protein in the samples. The positions of Pax-5 isoforms and TFIID are
indicated by arrows. Duration of LPS treatment in days is indicated above the lanes.
“Day 2” sample (lane 3) was partially lost due to a defect in the gel and may not
represent a true result for that time point.
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bound to the CD19/BSAP probe (Figure III.2B, lane 3-6).

Consequently, the DNA-

binding activity o f the Pax-5d isoform could be enhanced through availability o f more
DNA binding sites. The presence of two distinct bands running close to Pax-5d position
provides evidence for this model. However, due to the lack of a suitable Pax-5d-specific
antibody, it cannot be excluded that these bands represent paired domain-containing Pax5a degradation products which retained their DNA-binding ability. Interestingly, these
bands disappeared after LPS treatment o f B cells, similarly to the effect observed for
young activated SRBs (Figure II.7A, Chapter II). Furthermore, the Pax-5a band emerged
on day 4 o f LPS-activation (Figure III.2B, lane 7, 9, 11) and became progressively
stronger by day 8. Based on its interaction with the C-terminus-specific antibody C-20,
the observed band has been previously hypothesized to represent Pax-5a.l species which
contain an intact C-terminal regulatory module, consisting of the transactivation domain
and the adjacent repressor sequence. Activation-induced stabilization/modification o f the
Pax-5a C-terminal region has been reported in the experiments with SRBs from young
mice (Chapter II), which suggests that Pax-5a.l species have an important function
during activation and differentiation of B lymphocytes in response to mitogenic
stimulation.
In summary, activation experiments with SRBs isolated from aged mice have
demonstrated two important differences from young mice.

Aged SRBs have no

detectable Pax-5a.2 band, and the ratio o f Pax-5a to Pax-5Xproteins remains constant in
all activated aged samples, in contrast to its dramatic decrease observed during activation
o f SRBs from young mice.

Nevertheless, the samples from both age groups show

activation-associated stabilization of the Pax-5a isoform, with the ensuing accumulation
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10

11

12
Supershift
with C-20

Pax-5a
Pax-5d

C-20

Figure III.2B: EMSA of LPS-activated SRBs from aged mice.
Nuclear extracts (lp g ) from LPS-activated aged SRBs were analyzed by
EMSA using CD19/BSAP probe. Some samples (lanes 4, 6, 8, 10, 12)
were pre-incubated without the probe for 15 min at room temperature
with Pax-5a C-terminus-specific antibody, C-20. The resulting
supershift complex between the full length Pax-5a (see text) and C-20 is
indicated on the right. Duration o f LPS treatment in days is shown at
the bottom. Positions o f Pax-5a and Pax-5d complexes are indicated on
the left. Lane 1: CD19/BSAP probe alone; Lane 2: in vitro translated
Pax-5a (1 jllI lysate) and Pax-5d (2jll1 lysate).
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o f the full-length Pax-5a.l protein containing the repressor sequence. The experimental
data have also confirmed age-related reduction of Pax-5a DNA-binding activity in
senescent non-stimulated SRBs, as well as the loss o f Pax-5d DNA-binding in the
activated samples, previously determined by aging and activation studies conducted in
our lab. As for SRBs from young animals, the physiological significance of the observed
events has yet to be determined. However, it is clear that, while fundamentally similar,
the activation processes in young and aged lymphocytes display age-specific differences
that trigger distinct patterns o f Pax-5a and Pax-5d protein expression and DNA-binding.
These differences may contribute, at least partially, to the age-related decline o f humoral
response to mitogenic challenge and affect the quality o f the antibodies produced by aged
B lymphocytes.

3. W EH I-231 activation
Western blot analysis o f Pax-5 proteins in B cell lines representing various stages
o f B cell differentiation revealed that the patterns of the alternatively spliced isoforms
change in a stage-specific manner (see Chapter II). Furthermore, the isoform levels and
the respective protein ratios found in the immature B (WEHI-231) and early mature B
(B17.10) cell lines were most similar to those seen in partially activated normal B cells,
whereas the cell lines representing later stages were comparable to activated B
lymphocytes (Figure II.6A, Chapter II).

Based on this observation, we sought to

investigate whether activation of the immature B cell line W EHI-231 in vivo can induce
processes similar to those occurring during activation o f normal B lymphocytes. More
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specifically, this project aimed to determine whether activation o f the W EHI-231 cell line
triggers similar changes in Pax-5 isoforms, their protein levels, and DNA binding
patterns.
WEHI-231 is a murine B cell line with the IgM+/IgD+ surface phenotype
(Gottschalk and Quintans, 1995). Although this phenotype is typical for mature B cells,
W EHI-231 is commonly used to study immature B lymphocytes because it shares several
characteristics o f the immature B cell stage, such as the ability to undergo apoptosis
through pathways similar to those used in negative selection (Gottschalk and Quintans,
1995). Moreover, this cell line is frequently exploited for B cell activation studies, as
WEHI-231 cells display unique sensitivity to antigenic stimulation. Depending on the
source o f a subline and the nature of an antigen, WEHI-231 cells may respond to
stimulation by either undergoing growth arrest and apoptosis, or by proliferation and
further differentiation into antibody secreting cells (Gottschalk and Quintans, 1995; Aoki
et al., 1995). This responsiveness was utilized for activation studies in which the WEHI23 1 cell line was stimulated by either IgM cross-linking or by culturing in the presence of
bacterial lipopolysaccharide (LPS). Typically, 2-5x107 cells were either treated with 25
mM IgM F(ab ’)2 fragment for 3 min (Aoki et al., 1995), or activated by LPS as described
(Chapter II). The cells were incubated for specified periods of time and then processed
for nuclear extracts according to standard methods (Chapter II).
The results o f Western blot analyses of activated WEHI-231 samples showed that
the protein level o f the Pax-5a isoform remains unchanged regardless o f the type of
antigen used in the experiment (Figure III.3A; ED-1/TFIID panel). The levels o f Pax-5d
were relatively low in all samples and did not change significantly during 48 hr o f IgM
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Figure III.3A: W estern blot of activated WEHI-231 samples.
W EHI-231 cells were activated by either IgM cross-linking or
treatment with LPS. Nuclear extracts were collected at times
indicated above the lanes, and patterns of Pax-5 proteins were
analyzed using antibodies specific for Pax-5 functional domains.
Paired domain-specific ED-1 can recognize all Pax-5 isoforms; the
novel sequence-specific 6G 11 detects only Pax-5d and Pax-5e.
Anti-TFIID antibody was used to monitor the amount of total
protein in the samples.
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cross-linking and in the first 10 hr of LPS-activation (Figure III.3A; 6G11 panel).
Eventually, the intensity o f Pax-5d band decreased in both anti-IgM- and LPS-treated
samples (at 72 hr and 24 hr, respectively), although the reduction was not as noticeable
for the cross-linked samples (Figure III.3A, 6G 11 panel, lanes 5, 8, 9).
Similarly to splenic B lymphocytes, W EHI-231 cells contain the unidentified Pax5X species migrating at ~27 kD (compare to Figure II.5C, Chapter II). The intensity of
the Pax-5X band increased when WEHI-231 cells were activated by either IgM crosslinking (at 72 hr) or LPS stimulation (at 24 hr) (Figure III.3A, 6G 11 panel).

The

observed change, though not very dramatic, is similar to the pattern seen in LPS-activated
SRBs (compare to Figure II.5C, Chapter II), which suggests that this might be a widely
occurring phenomenon having a functional significance during B lymphocyte activation.
Analysis o f W EHI-231 nuclear extracts by EMSA revealed the presence o f three
distinct Pax-5 complexes in non-activated cells: a slower-migrating Pax-5a band (5a. 1)
and two faster-migrating complexes running close to Pax-5d position (Figure III.3B, lane
3). Since, according to Western blot data, the protein levels o f Pax-5d were very low in
the experimental samples, the lower bands are likely to represent either Pax-5a
degradation products or other Pax-5-specific complexes (rather than the Pax-5d isoform).
In agreement with the Western blot data, analyses o f nuclear extracts from WEHI-231
activation samples by EMSA showed no significant change in Pax-5a binding pattern for
resting and activated WEHI-231 cells (Figure III.3B).

The observed Pax-5a band

corresponded to the previously identified Pax-5a.l species, which is able to interact with
the C-terminal-specific antibody, C-20 (supershift with C-20 is not shown) (Anspach et
a l., submitted; Chapter II).
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In conclusion, activation o f W EHI-231 cells by either IgM cross-linking or LPS
treatment had no effect on either expression or DNA-binding patterns o f the Pax-5a
isoform.

This is not surprising as Pax-5a (BSAP) has been implicated in cell

proliferation (see Chapter I, Section 2.2), a function which is unlikely to be altered when
a mitogen is added to a continuously dividing B cell line. In contrast, activation-induced
changes were observed in the protein expression of the Pax-5Xspecies, which suggested a
functional role for this protein (or complex of proteins) in activated B lymphocytes.
Further characterization and comparative analyses o f W EHI-231 activation system may
provide a reasonable alternative to SRBs when used for studies o f B cell activation.

4. Characterization o f Pax-5Xspecies
A novel Pax-5Xspecies was detected in nuclear extracts of B cell lines and splenic
B cells analyzed by Western blot using the novel sequence-specific antibody 6G11 (see
Figures II.5C, II.6A, and III.3A). Since the band was poorly detectable with ED-1 anti
paired domain serum and no Pax-5x-specific complexes were observed in nuclear extracts
analyzed by EMSA (Figures II.5A, II.7A, and III.3A), it is likely that the novel Pax-5
protein possesses an incomplete DNA-binding domain. It was, therefore, hypothesized
that Pax-5X band represents Pax-5e, the novel-sequence-containing isoform with the
truncated paired domain (Figure 1.4). However, the biggest challenge o f this hypothesis
was to explain the discrepancy between the size o f the newly detected Pax-5X band (27
kD) and the estimated size o f Pax-5e isoform (19 kD).
To confirm that Pax-5Xis a Pax-5e-specific band, Pax-5e expression construct was
transiently transfected into a non-lymphoid cell line, NIH 3T3, as described (see
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“Materials and M ethods”, Chapter II). Nuclear extracts from the transfected cells were
analyzed by Western blot using Pax-5-speciflc antibodies, ED-1 and 6G 11 (Table I). The
transfected samples were compared to nuclear extracts from the immature B cell line
W EH I-231 and from resting normal B lymphocytes (SRBs).
The novel sequence-specific antibody 6G11 detected a single band at —27 kD
present in samples transfected with the Pax-5e expression construct (Figure III.4A; 6G 11
panel).

This band corresponded with the Pax-5X species that had been previously

observed in nuclear extracts o f WEHI-231 cells and SRBs (Figure III.4A, lanes 1-3). The
novel Pax-5Xprotein present in the transfected NIH 3T3 samples could also interact with
the paired domain-specific antibody ED-1 (Figure III.4A, ED-1 panel). Interestingly, the
intensity o f Pax-5Xbands detected with ED-1 varied depending on the source o f nuclear
extracts (Pax-5e-transfected samples, WEHI-231 cells or SRBs). This could be explained
by the differences in relative levels o f Pax-5Xin the assayed samples. Thus, based on the
results o f this experiment, Pax-5Xcan be characterized as a Pax-5 e-like species.
In addition to the Pax-5Xband, nuclear extracts from Pax-5e-transfected samples
contained two other protein species (Figure III.4A, ED-1 panel, lane 1). A fast migrating
band at —21 kD is likely to represent Pax-5e species that have been neither modified nor
complexed with other proteins. The nature of the second band (at -4 5 kD) is unclear;
however, it is clearly Pax-5e-specific and may represent either a Pax-5e homodimer or
extensively modified Pax-5e protein molecules. Curiously, a similar, high-running band
was also observed in the samples of NIH 3T3 cells transfected with Pax-5d expression
construct (Figure III.4A, ED-1 panel, lane 7). Both alternatively spliced variants, Pax-5e
and Pax-5d, possess the novel sequence containing two cysteine residues. Although
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dimerization o f either isoform has not been reported, it would not be surprising if these
proteins could form intermolecular disulfide bonds (see Chapter I, Section 4.1). If the 45
kD band indeed represents a Pax-5e homodimer, it is likely that the bonds that form
between two Pax-5e monomers are highly reactive, and tend to reform during
electrophoresis. As a result, a fraction of Pax-5e molecules remains dimerized despite
the denaturing conditions o f SDS-PAGE. If the same logic is applied to Pax-5X species,
detection o f the 27 kD band could be explained by the presence o f a heteromeric complex
o f Pax-5e with some ubiquitous factor.

In this case, a simple modification o f the

electrophoresis conditions (such as pre-assay treatments o f the samples with certain
reducing or denaturing agents) may help to reduce the number o f observed complexes
and promote the formation of a “true”, 19-21 kD, Pax-5e band (see Discussion for more
details). Alternatively, the bands that run above 21 kD may represent modified forms of
Pax-5e protein. However, since the exact function and properties of this isoform remain
unknown at this time, it is difficult to predict accurately what types of post-translational
modifications might affect the Pax-5e molecule.
Analysis o f nuclear extracts from NIH 3T3 cells transfected with Pax-5d
expression construct provided curious clues pointing to a possible origin o f Pax-5X
species in activated normal B cells. Due to the presence of two alternative start sites, the
Pax-5d transcript can generate either Pax-5d or Pax-5e protein, with Pax-5d being a
predominant translation product. This phenomenon is illustrated by the presence o f Pax5e band in [NIH+Pax-5d] samples analyzed by Western blot using ED-1 antibody (Figure
III.4A; ED-1 panel, lane 7). Intriguingly, [NIH+Pax-5d] nuclear extracts also contained
the Pax-5X band. According to the results described in Chapter II, the protein levels of
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the novel Pax-5X species increase dramatically during B cell activation, concomitantly
with a decrease in the levels o f Pax-5d isoform.

The absence o f activation-induced

changes at the RNA levels indicated that any change in the expression patterns o f Pax-5
proteins occurs at either translational or post-translational level (see Discussion). Thus, it
is conceivable that activation o f B lymphocytes may trigger the use o f an alternative
(distal) start codon on the Pax-5d transcripts, giving a rise to Pax-5X species.
however, requires further experimental prove.

This,
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Chapter IV
Discussion

In the studies presented in this thesis, the functions o f alternative Pax-5 isoforms
were explored using in vivo and in vitro assays that measured the transcriptional and
DNA-binding activities o f the isoforms and determined their protein expression patterns
in resting and activated B cells.

More specifically, the described project focused on

analyses o f transactivating function o f the Pax-5d isoform in relation to the activity of
Pax-5a, determination o f relative ratios o f Pax-5 proteins in resting and LPS-activated B
lymphocytes, and investigations o f activation- and differentiation-stage-specific changes
in the expression patterns and DNA-binding activities of Pax-5 isoforms occurring in
splenic B cells from young and aged mice and in various B cell lines.
The existence o f alternatively spliced variants with different DNA-binding
activities and variable functional domains suggests that Pax-5 isoforms may have
different, perhaps opposing, transactivating functions and play distinct roles during
development and differentiation o f B cells. Previous studies o f the related Pax-8 gene
have shown that it generates at least six developmentally regulated isoforms that display
differential transactivation potentials (Kozmik et al., 1993).

Other investigations have

revealed that alternative splicing affects the paired domains of Pax-8, Pax-6, Pax-3, and
Pax-7 resulting in generation o f isoforms with various DNA-binding activities and
specificities (Kozmik et al., 1997; Vogan et al., 1996). Thus, the isoforms of Pax-5 may
also have different transactivation properties and variable regulatory capacities, including
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the ability to interact with and sequester other factors and compete for sites on target
genes.

4.1 Pax-5d is a repressor o f Pax-5a activity
The results o f the functional studies demonstrated that, in contrast to Pax-5 a, Pax5d acts as an inhibitor of transcription. In addition, Pax-5d not only inhibits the activity
o f endogenous Pax-8 in the kidney cell line COS-1, but can also repress activity of Pax5a when the two isoforms are expressed simultaneously in NIH 3T3 cells. Thus, it can be
concluded that Pax-5a and Pax-5d have opposite regulatory functions in vivo. Moreover,
in certain circumstances, Pax-5d may function as a repressor that controls Pax-5a activity
either through DNA-binding competition or by sequestration of accessory factors
required for regulation of Pax-5 target genes.
Pax-5a and Pax-5d proteins share two functional domains including an intact
paired domain and the octamer sequence; however, they differ in the composition o f their
C-termini (see Chapter I, Figure 1.4). Pax-5d lacks the homeodomain homology box and
the entire C-terminal regulatory module consisting of the transactivation domain and
repressor sequence.

In place o f these regions, Pax-5d possesses a novel sequence of

unknown function (Zwollo et al., 1997). The observed repressor function o f Pax-5d is
likely to be due to the absence o f the transactivating domain; however, this needs to be
examined further. The opposite transactivating potential of Pax-5a and Pax-5d coupled
with their similar DNA-binding activities suggests a possible mechanism for regulation
o f Pax-5a function. Since the two isoforms appear to compete for binding, the presence
o f excess Pax-5d in a system may reduce the Pax-5a binding to its target sites on DNA.
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Consequently, the Pax-5a/Pax-5d ratio may be a key determinant of Pax-5 function in
regulation o f target genes.
Another consideration o f Pax-5d function comes from the presence o f the octamer
sequence shared by all Pax-5 proteins.

This region has been shown to bind the co

repressors from the Groucho family, and that interaction has been hypothesized to inhibit
the transcriptional activity o f Pax-5a

(Eberhard et al., 2000).

It remains to be

determined whether such contact can occur between the Groucho corepressors and other
Pax-5 isoforms, including Pax-5d.

However, it is conceivable that, at high enough

concentrations, the alternative variants of the Pax-5 gene could increase Pax-5a activity
by “absorbing” the Groucho co-repressors and, hence, preventing their interaction with
Pax-5 a. Alternatively, interactions between Pax-5 d and various accessory proteins may
inhibit Pax-5a-regulated gene transcription through sequestration of factors required for
efficient transcription o f target genes. Therefore, we cannot exclude the possibility that
the observed inhibition o f Pax-5a activity stems from Pax-5a/Pax-5d competition for
binding to accessory partner-proteins rather than to Pax-5-specific DNA-sequences.

4.2 Pax-5a and Pax-5d differ in protein stability
The data from the competition experiments indicate that inhibition o f Pax-5 a
activity can only be detected when the Pax-5a/Pax-5d ratio of the transfected effector
DNA is very low (less then 1/10). Difference in protein stabilities has been hypothesized
to be one o f the possible reasons for the disparity in concentrations o f the two isoforms.
Supporting, albeit indirect, evidence for this prediction is provided by the analysis of
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Pax-5a and Pax-5d protein levels in nuclear extracts from NIH 3T3 cells transfected with
either Pax-5a or Pax-5d expression construct.

The results of Western blot analysis

revealed that, for equal amounts of the transfected plasmid DNA, nuclear extracts from
the transfected samples contained approximately three times less Pax-5d than Pax-5a
protein.

However, this observation does not exclude the possibility o f differences

between the two isoforms at the level of transcription and/or translation (e.g.,
transcriptional/translational efficiency, rate o f protein synthesis, etc.).

Therefore, only

direct measurements o f the proteins’ half-lives can accurately determine whether the
issue o f protein stability has relevance for activity of Pax-5 isoforms.
The amino acid sequences of many rapidly degraded eukaryotic proteins contain
one or more regions rich in proline (P), glutamic acid (E), serine (S), and threonine (T)
(Rogers et a l., 1986). These regions, named “PEST” sequences, often represent sites of
constitutive and signal-induced phosphorylation, which can affect the intrinsic stability of
a protein.

For example, activation-induced phosphorylation o f serine and threonine

residues within the PEST domain of IkB (the NF-kB inhibitor) has been shown to target
this protein for degradation (Lin et al., 1996). An extensive PEST sequence has also
been found in the p53 protein (Rogers et al., 1986). Phosphorylation of specific residues
regulates a number o f the p53 properties, from the protein’s stability and conformation
states to its activity and interaction with other proteins (Meek, 1998). While no research
has been done so far to demonstrate the correlation between regulatory phosphorylation
o f p53 and the existence of the PEST domain, the link has been suggested by the
comparative analysis o f p53 with other PEST-containing proteins (Rogers et al., 1986).
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Curiously, PEST sequences are strikingly homologous to the sites o f (9-GlcNAc
glycosylation, which is one o f the most ubiquitous and abundant post-translational
modifications found in nuclear proteins (see Chapter I, Section jLJ; Haltiwanger et al.,
1997). It has been postulated that the major regulatory function o f O-glycosylation is to
compete with phophorylation sites on proteins, thus adding another level o f control to
signal transduction cascades inside the cells (Haltiwanger et al., 1997; Comer and Hart,
2000). It is possible that the reciprocal relation between protein phosphorylation and Oglycosylation has a role in regulation of protein stability.

Supporting this notion is a

study in which the total levels o f O-glycosylation have been correlated with the stability
o f the transcription factor Spl against proteasome degradation (Han and Kudlow, 1997).
Together

with

earlier

reports,

these

investigations

have

demonstrated

that

hypoglycosylated Spl is more susceptible to proteolytic degradation, whereas extensive
O-glycosylation o f this protein results not only in its stabilization but also in an increased
transcriptional activity (Jackson and Tjian, 1988; Han and Kudlow, 1997).
Based on sequence analysis, isoform Pax-5a (as well as Pax-5b) contains three
PEST consensus sequences (S/T-X-X-E/D) in a region immediately C-terminal from the
homeobox homology domain (aa 251-306).

The presence of the PEST domains may

indicate susceptibility o f Pax-5a protein to degradation. Isoform Pax-5d (and Pax-5e) has
no such regions due to alternative splicing; however, its stability may be regulated
through the novel sequence by mechanisms that have yet to be determined. For example,
the novel sequence o f Pax-5d contains three lysine residues. This amino acid is often
modified by ubiquitination in proteins that are destined for degradation (Pahl and
Baeuerle,

1996).

Alternatively, PEST sequences may function as sites for O-
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glycosylation, in which case Pax-5a could be marked by a longer half-life. In contrast,
the lack o f PEST domains in Pax-5d would render this protein more susceptible to
proteolytic degradation.

Examination o f the role o f the PEST sequences in Pax-5

protein stability may help to better understand pathways that regulate the processes
occurring during B cell activation.

4.3 B cell activation induces stabilization of Pax-5a isoform
Differentiation o f mature B lymphocytes into plasma cells is a complex, antigendependent process that consists o f multiple steps involving B cell activation,
proliferation, and expression o f stage-specific sets of genes.

In this process, the

activation signals initiate a variety of pathways which lead to immunoglobulin isotype
switching and antibody secretion. Previously, Pax-5 (BSAP) has been shown to control
the switch recombination events through regulation of Ig gene rearrangement (reviewed
in Hagman, 2000). Pax-5 also plays an important role in B cell proliferation which is
necessary for initiation o f Ig isotype class switching, somatic mutations, and formation of
germinal centers (Wakatsuki et al., 1994; Neurath et al., 1995). However, while Pax-5 is
an integral part o f an efficient immune response, terminal differentiation of B
lymphocytes into plasma cells and Ig secretion require downregulation o f Pax-5
expression (Usui et al., 1997; Stiiber et al., 1995).
The mechanism which downregulates the expression and activity of Pax-5 in
activated B lymphocytes is not clearly understood.

However, our experimental data

clearly show that initial control occurs at the protein level. The ratio o f Pax-5a to Pax-5d
mRNA remains unchanged during LPS stimulation of B cells, indicating that neither rate
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o f RNA synthesis nor RNA stability is affected by the activation signals and onset of
differentiation. This finding confirms previous observations by Anderson et al. (1996)
who reported that BSAP (Pax-5a) mRNA levels stay constant in resting and LPSactivated primary B lymphocytes.
In contrast, a number o f changes were detected at the protein levels of Pax-5
isoforms, when nuclear extracts from resting and activated B lymphocytes were analyzed
by W estern blot and EMSA.

In the previous studies, two Pax-5a species have been

detected in resting mature B cells, Pax-5a.l and Pax-5a.2 (Anspach et al., submitted).
Slightly different migration rates of these species under non-denaturing conditions
(EMSA) suggested that the representative proteins are likely to possess different
conformations or structures. In the study reported here, evidence is provided that Pax5a. 1 and Pax-5a.2 differ in the composition of the C-terminus, based on their interaction
with Pax-5 N- and C-terminus-specific antibodies. The most likely explanation o f these
data is that the Pax-5a.2 protein lacks the repressor sequence, whereas Pax-5a.l species
represent a full length Pax-5a protein with the intact C-terminal regulatory module.
Significantly, during B cell activation, the relative ratio between the two species shifts
toward Pax-5a.l, reflecting a modification at the C-terminus, followed by an overall
stabilization o f the Pax-5a isoform in activated samples. Interestingly, the stabilization of
Pax-5a and formation of Pax-5a.l species during B cell activation coincides with an
increase in the relative protein levels o f Pax-5a isoform in nuclear extracts of activated
samples. That finding is in agreement with the results of a previous study in which an
increase in BSAP/Pax-5a levels has been correlated with the time o f active proliferation
o f B cells in response to LPS-activation (Wakatsuki et al., 1994). Perhaps, this explains
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why the patterns o f Pax-5a isoform do not change during activation of W EHI-231 B cell
line: cells that divide continuously presumably should have only those Pax-5a species
that support B cell proliferation, namely Pax-5a.l. This is also supported by the results of
an independent experiment in which B cell lines, representing different stages o f B cell
differentiation, were analyzed by EMSA (result not shown).

That data revealed that

nuclear extracts from all assayed samples possess Pax-5a.l only, which is in agreement
with the suggested role o f this species in B cell proliferation.
The three most 3,-terminal exons of Pax-5a has been shown to be unaffected by
alternative splicing, thus eliminating a possibility that Pax-5a.2 band represents a novel
Pax-5 isoform. Alternatively, 5a.2 may represent either a dephosphorylated form or a
degradation product o f 5a. 1.

Site-specific phosphorylation is a common trigger of

proteolytic degradation that plays an important role in regulation of NF-kB, p53, and a
wide variety o f nuclear and cytoplasmic proteins (Hunter and Karin, 1992).

In many

cases, phosphorylation o f specific residues allows recognition of the modified protein by
the E3 ubiquitin-protein ligase which catalyses the binding between the ubiquitin and a
protein substrate (Pahl and Baeuerle, 1996). This mechanism has not unequivocally been
ruled out as a factor in generation of Pax-5a.l and Pax-5a.2 molecular species, although
the phosphatase treatment o f nuclear extracts from resting B cells had no effect on either
protein expression or DNA-binding patterns o f the two Pax-5a species (data not shown).
Another alternative is that Pax-5a.2 species is a product o f degradation of the full-length
Pax-5a protein (Pax-5a.l). It is possible that, in resting but not activated/proliferating B
lymphocytes, specific proteases remove the C-terminal sequence o f Pax-5a.l and reduce
stability o f this protein, causing multiple degradation bands. The degradation products
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could include the Pax-5a.2 species which contain all of Pax-5a functional domains,
except the repressor sequence. During B lymphocyte activation, the alterations in the
cell’s environment may either specifically inactivate these proteases or, alternatively,
promote certain protein modifications that stabilize/protect Pax-5 a. 1 from C-terminal
degradation. The exact mechanism of these modifications is not understood at this time,
and its elucidation may require determination o f Pax-5a half-life in resting and activated
B cells, which is the focus o f our current research.
In support o f a functional role for C-terminus-initiated degradation is the presence
o f a potent repressor domain in this region (see Chapter I, Figure 1.4). In the full-length
Pax-5a protein, the C-terminal transactivation domain is flanked by a 33-amino acids
repression sequence which has been shown to inhibit Pax-5-dependent transcription o f a
minimal promoter in transient transfection experiments (Dorfler and Busslinger, 1996).
Specific proteolysis o f the extreme carboxy-terminal repression module may produce a
highly active Pax-5a species with a potent transactivation function.

In contrast,

stabilization o f the protein, followed by subsequent retention o f the repressor sequence,
may yield a non-truncated Pax-5a version with attenuated capacity for activation of
transcription. It is possible that the functions of the full length Pax-5a in vivo involve
mostly the control o f cell proliferation and the maintenance of only a small subset o f B
cell-specific genes; however, this needs further investigation.
Another interesting possibility is based on the recent study which demonstrated
that the paired domain polypeptide was in some cases sufficient for reconstitution of
endogenous Pax-5 target gene expression in Pax-5-deficient pre-BI cells (Nutt et al.,
1998). I propose that, in resting B cells, proteolysis at the C-terminus o f Pax-5a does not
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only produce species with a higher transactivating potential (such as Pax-5a.2), but also
generates an array o f truncated polypeptides that have no transactivation domain but
contain an intact paired domain. These shorter versions o f Pax-5a protein may play a
significant role in regulating a subset of Pax-5 target genes which do not require the
complete Pax-5a sequence, including those where Pax-5 functions as a docking protein
(e.g. mb-1). Activation-induced stabilization of Pax-5a rapidly reduces the number of
regulatory fragments, and, during the late stages o f LPS-activation, full-length Pax-5a
(with the repressor domain) is the only molecular species available for transcriptional
regulation. Consequently, the transactivating effect of Pax-5a on its target genes may be
modified as soon as the activation signal is received, allowing for a quick change in gene
expression.

Thus, different length Pax-5a fragments may have distinct transactivation

potentials, ranging from a weakly active protein to a potent regulator to a polypeptide
with a recruiter capacity. In combinatorial regulation o f Pax-5 target genes, a particular
function o f each fragment would likely to be determined by the specific regulatory
sequence context.
This hypothesis could explain the expression pattern of the mb-1 gene which
encodes a component o f BCR, Ig-a molecule. The mb-1 gene is expressed during all
stages o f B lymphocytes development, but not in late activated B and plasma cells
(Fitzsimmons et al., 1996). According to our model, the gene is positively regulated by a
set o f truncated Pax-5a fragments in non-activated B cells.

Following antigenic

challenge, Pax-5a is stabilized and the full-length, repressor sequence-containing form of
the protein (5a. 1) starts to accumulate in activated B lymphocytes. The stabilized Pax-5a
is no longer able to function as a potent transcriptional activator, and transcription of the
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positively regulated mb-1 gene is inhibited (in activated B cells) and, subsequently, shut
off (in plasma cells).
Proteolysis is a common mechanism that quickly and irreversibly regulates
transcription factor function. This means o f regulation is particularly useful when cells
need to respond rapidly to changes in their environment. Several eukaryotic transcription
factors, including NF-kB, p53, c-Myc, and c-Jun, have been shown to be regulated by
proteolytic events, most of which involve the ubiquitin-proteasome pathway (reviewed
in Peters, 1994; Pahl and Baeuerle, 1996). Proteolytic degradation may occur either in
cytoplasm (e.g., NF-kB (Thanos and Maniatis, 1995)) or in the nucleus (e.g., H IF -la
(Salceda and Caro, 1997)), indicating that this process is mediated by the specifically
localized proteasome systems.

The lability o f many regulatory proteins is critically

important under normal conditions, and disruption o f proper steady-state levels o f these
proteins may have deleterious consequences for a cell (Treier et al., 1994). However, in
some cases, protein stability changes drastically when cells are subjected to a stressful
stimulus. Wild-type p53, for instance, is a short-lived nuclear transcription factor which
becomes stabilized and activated following cellular stress or DNA damage (Pahl and
Baeuerle, 1996). The exact mechanism of this stabilization is not clearly understood, but
thought to be regulated by multi-site phosphorylation (Steegenga et al., 1996; Meek,
1998). Another example is the hypoxia-inducible facto r-la (H IF -la), a transcriptional
activator complex involved in regulation of several hypoxia-regulated genes (Salceda and
Caro, 1997).

Under normoxic conditions, H IF -la is continuously degraded in the

nucleus by the ubiquitin-dependent pathway. The lack of oxygen, or hypoxia, induces
stabilization and accumulation o f H IF -la followed by subsequent activation o f its target
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genes (Salceda and Caro, 1997).

The signals triggering stabilization of the H IF -la

protein are currently unknown; however, some evidence suggests that redox-mediated
changes might be involved (Salceda and Caro, 1997).
Thus, stress-induced stabilization of transcription factors is a well-documented
phenomenon which may take place in activated B lymphocytes.

It remains to be

determined whether Pax-5a degradation, occuring in resting B cells, involves the
ubiquitin-proteasome system.

Further investigations are also needed to identify the

factors which contribute to susceptibility of Pax-5a to degradation, as well as to its
stabilization during activation.

4.4 The ratio o f Pax-5 proteins changes after LPS stim ulation
To investigate whether the suppressor activity o f Pax-5d has functional
significance during B cell activation, relative protein levels of Pax-5a and Pax-5d
isoforms were analyzed in mature resting and LPS-activated B cells.

Contrary to the

preliminary hypothesis about the role o f the Pax-5a/Pax-5d ratio in regulation o f Pax-5a
function, the levels of Pax-5d were very low in resting B lymphocytes and undetectable
in nuclear extracts o f activated cells. However, a new band was detected at ~27 kD that
represents a yet unidentified protein species named Pax-5X. The intensity o f Pax-5Xband
increases dramatically during the late activation stages concomitantly with the decrease
in the Pax-5a levels.

It is noteworthy that the Pax-5X band has also been detected in

nuclear extracts o f various B cell lines, including those from anti-IgM- and LPSstimulated cells o f the WEHI-231 cell line.

In agreement with the results o f SRB
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activation, the intensity of the Pax-5X band was higher in cell lines representing late
stages o f differentiation and in activated W EHI-231 cells.
The exact nature o f Pax-5X species is unknown at this time.

Western blot of

resting and activated SRBs shows that the band can interact with the novel sequencespecific antibody 6G11, but is undetectable using the paired domain antiserum ED-1.
These results indicate the presence of the novel sequence and suggest that the paired
domain is either incomplete or absent in the novel species. The fact that Pax-5Xdoes not
possess any detectable DNA-binding activity suggests that the Pax-5Xband may represent
the Pax-5e isoform. However, the expected size of Pax-5e is 19 kD, and, while the Pax5Xband has been shown to be Pax-5e-specific, the reason for such a discrepancy in size
between Pax-5e and Pax-5Xremains unclear. One possible explanation is that the band
represents a modified form o f the Pax-5e protein.

The configuration o f the modified

protein might be such that it prevents the efficient interaction of ED-1 with the epitopes
in the paired domain of Pax-5e, which, coupled with the reduced size o f the region, could
result in a poor response o f Pax-5Xspecies to this antibody. Alternatively, the levels of
the paired domain epitopes interacting with ED-1 may simply be too low in normal B
cells. In support o f this explanation is the data from W EHI-231 activation experiments.
The levels o f Pax-5 proteins are much higher in W EHI-231 cell line compared to splenic
B lymphocytes. Although detection of the Pax-5Xspecies by ED-1 was still poor in these
samples, the band could be seen on overexposed films (not shown).
The patterns for the Pax-5Xband were very similar in EPS-stimulated SRBs, in
activated W EHI-231 cells, and in B cell lines representing different stages o f B cell
differentiation (all determined using 6G11 antibody).

The protein levels of Pax-5X
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species increase markedly during late stages o f B cell differentiation in all experimental
systems, suggesting a common mechanism involved in response of B lymphocytes to
antigenic challenge and in their progression toward the plasma cell stage. Since no bands
corresponding to Pax-5Xspecies were observed in data from EMSAs, it can be concluded
that these species lack either the entire DNA-binding domain or a part thereof, which is in
agreement with the Pax-5e-specific nature o f the Pax-5X protein. Consequently, Pax-5X
cannot compete for DNA-binding with Pax-5a isoform; however, it may participate in
protein-protein interactions that can take place within the octamer and/or the novel
sequence regions.

It is conceivable that, at high enough levels, Pax-5x may be able

compete with other isoforms for certain co-factors such as, for example, co-repressors of
the Groucho family implicated in regulation o f Pax-5a activity (Eberhard et al., 2000).
Thus, the increase in levels o f Pax-5X observed in activated B lymphocytes provide
additional support for the important regulatory role of Pax-5X species and suggest a
functional significance for the Pax-5a/Pax-5x ratio during late stages o f B cell
differentiation.

Therefore, while the original model suggesting the role for the Pax-

5a/Pax-5d ratio may be incorrect, regulation of Pax-5a activity via change in the relative
levels of other isoforms is likely to be important, but will require more experimental
support.

4.5 The elusive Pax-5X: speculations on the origin of a species
Identification o f Pax-5X species is a focus of our current investigations.

As

discussed above (Section 4.4), the position of the band on SDS-PAGE gel (-2 7 kD)
suggests that Pax-5X may represent a modified form o f Pax-5e protein.

Possible
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modifications that could account for an -8 kD discrepancy in size may include Oglycosylation or formation o f disulfide bonds.
Pax-5e, which contains three cysteine residues, may be able to form homo- and
heterodimers, as well as intramolecular disulfide bonds. In support o f this hypothesis, is
the presence o f a higher molecular weight band (-50 kD) observed in nuclear extracts of
NIH 3T3 cells transfected with the Pax-5e expression construct. Failure of this band to
interact with the novel sequence-specific antibody 6G 11 suggests that the novel sequence
is either masked (as in dimmers interacting through that region) or modified (e.g., by
internal disulfide bonds). In the latter case, Pax-5e protein could fold on itself creating a
very compact molecule that would have a much lower rate of migration in a
polyacrylamide gel, resulting in a slower moving band. It is possible that disulfide bonds
forming

during

such

interactions

are

highly

reactive

and

can

reform

during

electrophoresis despite the presence of p-mercaptoethanol (reducing agent) in sample
buffer, although no precedence for this was found in the literature.

To prevent the

cysteines from participating in bond re-formation, the samples could be treated with a
strong oxidizing agent such as performic acid, which will cause irreversible cleavage of
existing disulfide bonds (Lou et a l., 1987). Perhaps, such stringent conditions will help
to keep all the proteins in nuclear extracts as separate, fully denatured entities, easily
separable and individually detectable.
Another possible modification involves O-glycosylation o f Pax-5e protein.
Addition o f O-GlcNAc residues usually occurs at the sites containing a proline residue Nterminal to the modified serine or threonine (see Chapter I, Section 3.3). Curiously, Pax56 (as well as Pax-5d) contains four P-S/T regions in its amino acid sequence. Although
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it is not known whether these regions are subject to glycosylation, it is tempting to
speculate that the retarded migration rate o f Pax-5e (at -2 7 kD instead o f the expected 19
kD on denaturing gels) is caused by the addition of bulky sugar moieties. Unfortunately,
it is difficult to estimate the possible number of putative O-GlcNAc residues (MW= 0.2
kD) based on the difference in the bands’ size (~ 8 kD) because the correlation is not
necessarily linear.

However, it might be interesting to examine the effect o f various

deglycosylating enzymes and glycosylation inhibitors (see Future Directions) on the Pax5e banding pattern. The notion of glycosylation of Pax-5 proteins is supported by the
analyses o f O-glycosylation in activated T lymphocytes. These studies demonstrated that
mitogenic stimulation of T cells induces a rapid increase in O-GlcNAc-modified nuclear
proteins concomitantly with the decrease in the levels o f glycosylated proteins in the
cytoplasm (Kearse and Hart, 1991).
So far, I have not considered the case in which the Pax-5x band is composed o f a
Pax-5d degradation product. The protein would have to be degraded from the N-terminus
(since it still can interact with 6G11 antibody), with the paired domain being affected to
such an extent that it is no longer able to interact with either Pax-5-specific sites on DNA
or ED-1 antibody. This possibility is the one that is difficult to address using the methods
employed in this project (i.e., Western blot and EMSA).

The N-terminus-specific

antibody N-19 (see Chapter II, Table I) does not recognize Pax-5 proteins in their
denatured form and, hence, could not be used for Western blot detection o f Pax-5X
species.

Likewise, these species could not be analyzed by EMSA due to the lack of

DNA-binding activity. Thus, at this time, it is virtually impossible to distinguish between
Pax-5d N-terminal degradation products and Pax-5e isoform, unless microsequencing
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techniques are used. However, it is useful to consider the following observations. First,
a gradual increase o f Pax-5Xlevels in late activated SRB samples does not correspond
with a sudden fall in the intensity o f the Pax-5d band to undetectable levels immediately
following LPS activation. Furthermore, since the RNA levels o f the Pax-5a and Pax-5d
isoforms

have

been

shown

to

remain

constant

during

B

lymphocyte

activation/development, the degradation of Pax-5d N-terminus would most likely occur at
the protein level through specific proteolysis. In this case, it is not clear how and why the
identical region on Pax-5a protein is protected from the proteolytic effect of proteases
involved in the process. Lastly, the Pax-5Xband was observed in nuclear extracts o f NIH
3T3 cell line transfected with Pax-5e expression construct.

This result confirmed that

the Pax-5Xband is Pax-5e-specific, and is more likely to represent a post-translationally
modified form o f Pax-5e protein than a degradation product o f Pax-5d.
What is the source o f the Pax-5X species in activated B cell samples? Based on
the results o f RNAse protection assays, the increase in Pax-5Xprotein levels is not a result
o f transcriptional changes, but a product of translational and post-translational regulation.
The presence o f two translational start sites on the Pax-5d mRNA transcripts allows
generation o f either Pax-5d or Pax-5e from each single transcript. In fact, when non
lymphoid cell line NIH 3T3 is transfected with the Pax-5d cDNA construct, four species
are produced: a largely predominant Pax-5d protein (at 35 kD), Pax-5Xspecies (27 kD),
the Pax-5e isoform (-19 kD), and an additional molecule (or protein complex) of
unknown nature ( - 50 kD). The bands for Pax-5e and Pax-5Xcorrespond to those seen in
nuclear extracts from NIH 3T3 cells transfected with the Pax-5e-containing construct.
Therefore, based on these observations, I hypothesize that, during LPS activation, B
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lymphocytes receive a signal that initiates a preferential use o f the distal ATG codon on
the Pax-5d transcripts resulting in the increased production o f Pax-5e protein.

In

increased concentrations, Pax-5e may be able to bind to or sequester various factors,
some o f which might be important for regulation of transcriptional activity of Pax-5 a
isoform (e.g., Groucho co-repressors). Importantly, I hypothesize that isoform Pax-5d is
unable to fulfill this role because its upregulation would result not only in sequestration
o f accessory factors, but also in DNA-binding competition with Pax-5a. The resulting
inhibition o f Pax-5a activity might be detrimental for Pax-5a function exerted on a subset
o f target genes in activated B cells. It is unclear whether activating stimuli have a similar
effect on other Pax-5 isoforms. The experimental data do not show protein levels o f Pax 5b isoform changing in a manner identical to that of Pax-5e, which suggest that the
proposed mechanism is likely to be very specific.

This, however, requires further

investigation.

4.6 Effects o f aging on B cell activation: the case of Pax-5 proteins
Currently, the experimental evidence demonstrating the effects o f age on B cell
responses to various antigens remains fragmentary. The progress in this field has been
slow in part because it is difficult to determine whether age-related changes in B
lymphocytes function are caused by biochemical modifications within B cells, or by
alterations in the activity o f T cells. Several studies that utilize B cell mitogens suggest
that the magnitude o f B lymphocyte function, defined by cell proliferative response,
decreases with age (Andersson et al., 1977; Schulze et al., 1992; Powers et al., 1992).
Although the exact mechanism of this decline is unknown, it is conceivable that Pax-5

proteins, among other transcription factors, may be partially responsible for impaired
proliferation o f activated B lymphocytes. This hypothesis is supported by experimental
findings which have demonstrated that reduced levels of Pax-5a expression lead to
decreased response to LPS (Wakatsuki et al., 1994).
While no quantitative measurements o f B cell proliferation were conducted on
either young or aged lymphocytes, the previously determined lack of Pax-5a DNAbinding (Anspach et al., submitted) implies that, in aged mice, the proliferative response
to LPS stimulation can be expected to be lower than in young animals. In support of this
prediction, a characteristic initial rise in Pax-5a protein levels, corresponding to the peak
o f activation-induced proliferation of B lymphocytes, was not observed during activation
o f aged B cells, suggesting an attenuated growth of LPS-activated cultures. Interestingly,
in the studies described here, a gradual return of Pax-5a DNA-binding was observed
during late stages o f LPS activation. Specifically, the observed band represents Pax-5a.l
species which has been correlated with the activation-induced B cell proliferation in
young mice (Chapter II).

This result confirms the functional significance o f the full-

length (i.e., Pax-5a.l) Pax-5a protein in the process of B cell activation and proliferation,
and in the development o f humoral immune response in young, as well as aged, animals.
In the discussion o f Pax-5a.l and Pax-5a.2 species (Section 4.3), I proposed that
instability o f Pax-5a isoform observed in resting B lymphocytes may have a function as a
mechanism o f generating a variety of Pax-5a proteins with distinct transactivating
properties. The Pax-5a.2 protein was suggested to be of a particular importance, as it
represents a highly active form o f the Pax-5 transcription factor possessing all functional
domains except the repressor sequence. In aged SRBs, the Pax-5a. 1 species were absent,
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5a.2 significantly decreased, and the overall Pax-5a degradation pattern displayed fewer
DNA-binding fragments compared to young SRBs. Curiously, the relative levels o f Pax 5a and Pax-5Xproteins remained constant in resting and activated aged SRBs. If the Pax5a/Pax-5x ratio has a functional significance in B cell differentiation, then such
invariability in the relative proportions o f the two proteins may be a sign o f inadequate
regulation and/or impaired signaling occurring during activation of aged B lymphocytes.
Perhaps, a high concentration o f the Pax-5Xspecies in resting B cells is the reason for a
reduction in DNA-binding activity of various Pax-5a fragments, including the important
Pax-5a.2 protein. Moreover, constantly high levels o f Pax-5Xmight be responsible for
excessive sequestration o f critical accessory factors, which may result in either
inappropriate activation o f Pax-5a or unregulated competition with other Pax-5 proteins.
Age-associated decreases in DNA-binding properties have been reported for
several transcription factors including Sp-1, NFAT, and Ap-1 (Ammendola et al., 1992;
Pahlavani et al., 1995; Pahlavani et al., 1996). Sp-1 is a general transcription factor that
activates a wide variety o f genes and is present in all mammalian cells.

Independent

studies o f this protein have shown that its transcriptional activity in normal, nonsenescent tissues can be regulated by post-translational modifications including O-linked
glycosylation, phosphorylation of serine residues, and multimerization of Spl on its
DNA-binding sites (Ammendola et al., 1992). In aged rat brain and liver tissues, Spl is
characterized by a very low (60 fold decrease compared to young tissues) binding
efficiency, although the expression of the S p l gene is not affected (Ammendola et al.,
1992). The observed change in DNA-binding activity was correlated with the decreased
expression o f at least one o f the Spl target genes and proposed to be a result o f age-
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related defects in post-translational modifications (Ammendola et al., 1992).

Another

example is the T-cell-specific transcription factor NFAT that plays an important role in
the regulation o f IL-2 transcription. One of the T cell secreted cytokines, IL-2 provides
important signals for T cell proliferation and antibody production and, hence, plays a
central role in induction and development o f the immune response (Arai et al., 1990).
The production o f IL-2 declines with age (Rea et al., 1996), which coincides with a
decrease in NFAT DNA-binding (Pahlavani et al., 1995). Interestingly, the reduction of
NFAT binding activity is also thought to be caused by age-related alterations in posttranslational regulatory mechanisms (Pahlavani et al., 1996).
Thus, the experimental data described in this thesis, together with reports from
other labs, support the hypothesis that aged animals display an age-associated decline of
B cell responsiveness to mitogenic stimulation, as reflected in decreased proliferative
capacity o f B lymphocytes.

This reduction in proliferative ability o f activated B

lymphocytes may be related to alterations in DNA-binding activities and relative levels of
Pax-5 proteins.

Furthermore, age-induced changes in characteristics and properties of

Pax-5 isoforms may be triggered by altered regulatory mechanisms occurring at the
translational and/or post-translational levels. The lack o f Pax-5a DNA-binding in resting
B cells, coupled with the unchanging Pax-5a/Pax-5x ratio in activated B lymphocytes,
may contribute to inhibition o f genes that trigger cell division and regulate antibody
production, ultimately leading to poor humoral immunity in senescent organisms.
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4.7 M odel o f Pax-5 function
The models regarding function and regulation of the Pax-5 transcription factor
that have been proposed in this work and by other research groups can be summarized in
the following key points (Figure IV. 1A):
• The Pax-5 gene generates four alternatively spliced products: Pax-5a, Pax-5b,
Pax-5d, and Pax-5e.

The four isoforms differ in DNA-binding activities and

transactivation properties, and display distinct expression patterns during different stages
o f B cell development and differentiation. The differentiation stage-dependent regulation
o f Pax-5 proteins occurs at the translational and/or post-translational, but not
transcriptional, level(s).
• The predominant isoform Pax-5a can function as an activator, a repressor, or a
docking protein, depending on the target gene.

The less abundant isoform Pax-5d is

unable to interact with the basal initiation complex due to the absence of the
transactivation domain, and hence functions as a repressor o f transcription.

Isoforms

Pax-5b and Pax-5e lack DNA-binding activity due to incomplete DNA-binding domain,
and thus can only function as either co-repressors or co-activators in transcriptional
regulation, via protein-protein interaction.

In addition, Pax-5b and Pax-5e may act as

dominant-negative inhibitors o f Pax-5a and Pax-5d, respectively, as they share several
functional domains, including those that have been implicated in protein-protein
interactions.
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Figure IV.1A: Functions of alternative isoforms of the transcription
factor Pax-5. Pax-5 isoforms have different DNA-binding and transactivating
properties. Only isoforms Pax-5a and Pax-5d can efficiently bind to Pax-5specific sequences on DNA. Due to the absence of DNA binding activity,
Pax-5e and Pax-5b can only have a dominant-negative or co-repressor
function. Pax-5e and Pax-5d possess a novel sequence in place o f a region
containing the transactivation domain and homeodomain. The presence o f the
novel sequence confers a repressor function to isoform Pax-5d. In Pax-5a, the
activity o f the transactivation domain is regulated by the adjacent C-terminal
repressor sequence. The functions o f Pax-5 isoforms are shown on a
hypothetical positively regulated Pax-5 target gene. See text for details.
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• Transactivation function of the Pax-5a isoform may be regulated by at least two
different mechanisms: a) by other isoforms, via competition for either DNA-binding
sites or accessory factors;
b) through post-translational modifications that increase Pax-5a
protein stability and allow retention of the repressor sequence.

Based on these key points, I would like to propose the following model for
regulation o f Pax-5 proteins in resting and activated B lymphoctes (Figure IV .IB).

In

resting B cells, isoform Pax-5a is highly susceptible to C-terminal proteolytic
degradation.

Proteplytic degradation generates a variety of paired domain-containing

Pax-5a fragments. These truncated polypeptides have distinct transactivation properties
which ensure differential regulation for a wide range of Pax-5 target genes. Activity o f
some fragments may be modulated by DNA-binding competition with the Pax-5d
isoform, which will exert an opposite effect on transcription of genes affected by such
competition. In addition, both Pax-5d and Pax-5e may compete with Pax-5a fragments
for a variety o f yet unidentified co-factors and partner-proteins.

However, since the

levels o f these two isoforms are very low in resting B cells, their effect might be either
negligible or very specific. Pax-5e and Pax-5d may also form homo- and heterodimers
through interactions between the novel sequences.
Activation o f B lymphocytes results in a rapid stabilization of Pax-5a, followed
by the subsequent accumulation o f a full-length Pax-5 protein containing the C-terminal
repressor sequence (5a. 1). In activated B cells, the functions of the Pax-5a isoform are
limited to control o f B cell proliferation and regulation of a small subset of target genes.
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Since DNA-binding competition with Pax-5a fragments is no longer needed, the Pax~5d
isoform is either degraded or used to produce more Pax-5e (through alternative use of the
proximal start site during translation).

Without interfering with Pax-5a DNA-binding,

Pax-5e sequesters certain accessory proteins or regulatory factors, inhibiting basal Pax-5a
activity, other than that necessary for B cell proliferation and maintenance o f target
“housekeeping” genes which are independent of B cell development.

As activated B

lymhpocytes progress to the plasma cell stage, the majority o f positively regulated Pax-5
target genes are turned off or downregulated simultaneously with the relief o f Pax-5
repressor function on its negatively regulated target genes. Finally, upregulation of Pax 5e isoform may have a function independent of other Pax-5 proteins, such as, for
example, regulation o f B cell apoptosis during late stages o f B cell differentiation. In this
model, the role o f isoform Pax-5b is still unclear, but may involve a dominant-negative
function during late stages o f B cell activation and in the plasma cell stage.
This model needs to be refined by further experimental evidence and by
clarification o f the mechanisms involved in the proposed regulatory events. However, it
can be used as a “template” for future investigations that will focus on a wide variety of
pertinent issues, including the aspects suggested in the next section.
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Figure IV.1B (see next page): A model of function and regulation of Pax-5 proteins
in resting and activated B lymhpocytes. See text for details.
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4.8 Future directions.
Identification o f P ax-5Y species. Elucidation of the nature and origin o f Pax-5X
species will have great implications for further understanding o f the activation process in
B lymphocytes. Currently, the main focus of our research is to determine whether the
novel Pax-5Xband represents a modified form of Pax-5e protein. To solve this problem,
we first have to optimize experimental conditions in ways that will favor detection of
individual, fully denatured proteins. These will involve determining whether inter- and
intramolecular disulfide bonds form in Pax-5e molecules and whether they can be re
established during electrophoresis.

To address this question, nuclear extracts will be

subjected to a wide range o f pre-assay treatments including incubations with strong
reducing/oxidizing agents and modifying enzymes and prolonged boiling at high
temperatures.

Another important aspect o f these investigations will aim to determine

whether the Pax-5Xspecies represent an O-glycosylated form of Pax-5e.

This will be

done through examination o f effects of deglycosylating enzymes on the Pax-5e/Pax-5x
banding patterns.

Alternatively, we could use the inhibitors o f glycosylation, such as

PUGNAC (Comer and Hart, 2000), to promote hyperglycosylation o f Pax-5 proteins and
determine how this will affect their rates of migration on denaturing gels.

Finally,

monoclonal antibodies directed against 0-GlcNAc (Turner et al., 1990) may be a useful
tool for detection o f glycosylated Pax-5 proteins.

In all the experiments mentioned

above, the experimental samples will consist of nuclear extracts from activated and non
activated WEHI-231 cells, cell lines transfected with various Pax-5 DNA constructs, and,
finally, resting and activated normal B lymphocytes.
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After the nature o f the Pax-5Xband has been discerned, investigations can proceed
to either further identification o f the partner protein(s) or to functional analysis o f the
Pax-5e isoform.

The latter will be conducted using the approach described for the

functional studies o f Pax-5d and will involve transient co-transfections o f lymphoid or
non-lymphoid cell lines with the Pax-5e effector construct and an artificial promoter
reporter construct (Chapter II). These studies may also include competition experiments
targeting the question o f whether transcriptional activity o f Pax-5a can be regulated by
overexpression o f the Pax-5e isoform. Identification of possible Pax-5e binding partners
may involve co-immunoprecipitation of the Pax-5X complex using 6G11 antibody.

In

these experiments, Pax-5Xspecies will be precipitated from nuclear extracts o f activated B
lymphocytes, and then analyzed by Western blot in order to determine what factors might
be sequestered in this complex by Pax-5e.
Other investigations may aim to determine the role of Pax-5e in apoptosis and to
examine the possibility o f Pax-5e regulation through the use of alternative start sites on
the Pax-5d transcript. To address the question of whether the Pax-5e isoform is involved
in regulation o f apoptosis, the Pax-5e protein will be overexpressed in a B cell line,
followed by an assay for the expression of defined apoptotic markers. To confirm the
hypothesis about a possible origin o f Pax-5e in activated B lymphocytes (see Section
4.5), the distal start codon o f Pax-5d will be mutated by site-directed mutagenesis. The
expression construct containing the mutant Pax-5d coding region will then be transiently
transfected into NIH 3T3 cell line. Nuclear extracts from the transfected samples will be
analyzed by Western blot using ED-1 antibody, and the results will be compared to the
data obtained for the wild type Pax-5d (see Chapter III, Section 4).
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Determ ination o f the role o f the novel sequence.

The function o f the novel

sequence is currently unknown. Previous research seems to indicate that this region does
not display transactivating properties and, in fact, may confer repressor characteristics to
Pax-5d isoform. However, at this time it is unclear whether the inhibitory function of the
novel sequence is determined by the absence of the transactivation domain, or by the
presence o f a yet unidentified m otif with the repressor function. It will be interesting to
investigate the properties o f truncated Pax-5d and Pax-5e mutant-proteins containing
incomplete novel sequence. A Pax-5d mutant lacking the entire novel sequence (Pax5dANS) has already been cloned in our lab, and will be used for functional studies in the
near future.

It would not be surprising if this mutant possesses functions o f a weak

activator as it is identical to a truncated Pax-5a protein with an intact paired domain. The
transactivating properties o f such fragments were discussed in detail in Section 4.3.
The presence o f two additional cysteine residues in the novel sequence presents
unique opportunities for formation of inter- and intramolecular disulfide bonds (see
Chapter I, Section 4.1).

In this context, it will be interesting to explore the effect of

targeted point mutations o f the selected cysteines on the behavior and interactions o f Pax5 proteins. In the scope o f these investigations, a panel o f mutant Pax-5 proteins will be
created by site-directed mutagenesis and cloned into an expression vector. The mutations
will target either both or individual cysteine residues in the novel sequence and, possibly,
one or two selected cysteines in the paired domain. The mutant-containing expression
vectors can first be co-transfected into non-lymphoid cell lines to examine whether
mutations o f cysteine residues will affect the folding o f the proteins, as well as their
DNA-binding activity, and stability.

Furthermore, similar co-transfections can be
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performed in a B cell line (i.e., WEHI-231), followed by subsequent activation of the
transfected cells. Nuclear extracts from activated and non-activated cells will then be
analyzed to determine the levels and expression patterns of the mutant proteins.

The

results will be compared to the observations reported for normal Pax-5 isoforms.

Protein stability studies.

Our previous research provides fragmentary evidence

suggesting the important role o f protein stability in the function and activity of Pax-5
proteins.

The protein stability of Pax-5a seems to be greatly affected during B cell

activation (see Chapter II and Section 4.3), and the difference in half-lives o f Pax-5a and
Pax-5d might be a key consideration in determining experimental conditions for Pax5a/Pax-5d competition studies (see Section 4.2). Thus, future studies should focus on
determination o f the isoforms’ half-lives. These investigations can be conducted using
pulse chase assays in resting and activated normal B cells and in cell lines transfected
with DNA constructs expressing the isoforms o f interest.
Protein stability studies may also encompass issues dealing with identification of
mechanisms and factors regulating stability of Pax-5 proteins in resting and activated B
lymphocytes.

If my hypothesis concerning Pax-5a degradation in resting B cells is

correct, it might be possible to stabilize this isoform by treating SRB cultures with
specific inhibitors o f the ubiquitin-proteasome system. Alternatively, the problem of
proteolytic degradation might be addressed by looking for a correlation between the
presence o f PEST sequences and protein half-lives. Recently, a Pax-5a mutant lacking
PEST sequences has been created in our lab. It will be interesting to examine the effects
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o f this mutation on the stability o f the Pax-5a isoform, and to compare protein half-life of
the mutant to that o f normal Pax-5d protein.

Study o f the alternative B cell activation pathways.

The conclusions and

hypotheses presented in this thesis are based mostly on the data obtained for LPSactivated normal B lymphocytes.

However, it cannot be excluded that the activation

pathways occurring in B lymphocytes are antigen-specific, and may involve variable
mechanisms o f Pax-5 regulation. One of the future projects may aim to investigate Pax-5
protein expression and DNA-binding patterns in normal SRBs stimulated by the B cell
receptor cross-linking. In this system, simultaneous addition of a CD40 ligand alone with
the specific cytokines (e.g. IL-4, IL-5, IL-6) may assimilate interaction o f B cells with
thymus-dependent antigens (see Chapter I, Section 1). Any differences from the patterns
observed in this study will indicate that the model o f Pax-5 protein regulation proposed
here is accurate only for humoral response triggered by the challenge with thymusindependent antigens.
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Conclusions
Several major observations of this project are summarized as follows:
1. Isoform Pax-5d has a function opposite to that of Pax-5a. Activity o f Pax-5a may be
regulated by Pax-5d via competition for binding either to target sites on DNA or to
accessory/regulatory factors.
2. The ratio o f Pax-5 proteins changes in activated B lymphocytes, reflecting a shift
toward higher concentrations o f the isoforms which may inhibit activity of Pax-5a.
Isoform Pax-5e is likely to play an important role in regulation o f Pax-5a function in
activated B lymphocytes.
3. Activity o f Pax-5a appears to be regulated at the post-translational level through
modulation o f its stability. Data suggests that Pax-5a is highly susceptible to Cterminal proteolytic degradation in resting B cells, but becomes stabilized in activated
B lymphocytes.
4. The ratio o f Pax-5 proteins changes during activation o f the immature B cell line
W EHI-231 in a pattern similar to that observed for mature B lymphocytes. The
changes in ratio o f Pax-5 proteins can also be correlated with the developmental stages
o f B lymphocytes (as assessed through analyses o f B cell lines representing different
stages o f B cell differentiation).
5. Expression patterns and DNA-binding properties o f Pax-5 proteins are altered in
resting and activated B cells isolated from aged mice.
6. Pax-5a and Pax-5d proteins are likely to have different half-lives.
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